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Abstract 
The main goal of this dissertation is the identification of novel modulators acting on 
ATP Binding Cassette subfamily C member 2 (ABCC2) transporters and α2-
adrenoceptors subtypes. In order to reach this goal, a combination of experimental and 
computational approaches are used.  
The first protein presented in this dissertation is the ABCC2 transporter, also known as 
the multidrug resistance associated protein 2 (MRP2). ABCC2 is an efflux transporter 
expressed in polarized cells where it effluxes a variety of both endogenous and 
exogenous molecules out of the cell. A common way to study the interactions between 
small molecules and the ABCC2 transporter is by vesicle transport assays. 
Commercially available assays use different probes to define the ABCC2 transport. A 
small set of eight compounds and, subsequently a larger library of compounds were 
tested with different assays with the intent to identify the effect that small molecules 
have on the ABCC2 transport. In addition from the larger library, 16 inhibitors have 
been identified and classification models were built to identify important descriptors, 
which were able to discriminate inhibitors from inactive molecules. Structure-activity 
relationships (SAR) of four scaffolds of ABCC2 modulators are also presented. In 
addition, some unpublished results are presented with further insights the SAR of 
ABCC2 modulators. 
The other proteins included in this dissertation are the three subtypes of the α2-
adrenoceptors. α2-adrenoceptors are G protein-coupled receptors involved in the 
signalling pathway of adrenaline and noradrenaline. To date not many subtype 
selective molecules are present in the market. Subtype selective molecules could be 
used in treatment of high blood pressure, in the alleviation of withdrawal symptoms, 
and as anaesthetic with fewer side effects than the current drugs. To define the affinity 
of a small set of antagonists and outline the involvement of the first transmembrane 
helix in ligand binding, a competition binding assay has been used with chimera 
receptors where the first transmembrane helix has been swapped between the three 
subtypes. Molecular modelling has been used to explain the different binding affinities 
to the chimera receptors. Additionally, the aim was to identify novel α2B-adrenoceptor 
selective compounds, thus a mid-sized library has been screened using a miniaturized 
binding assay. Hierarchical classification and chemoinformatics analysis has been used 
to visualize and analyse the screening results.  
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1. Introduction 
ATP Binding Cassette subfamily C member 2 (ABCC2) and the α2-adrenoceptors are 
intrinsic membrane proteins and are essential in the regulation and control of many 
biochemical functions. The function of membrane proteins can be modulated by 
endogenous or exogenous compounds. The general aim of this dissertation is the 
identification of novel compounds and the characterization of their mode of action, 
which is central in the understanding of the biological role of these proteins. With this 
intent, screening methodologies, chemoinformatics, and homology modelling 
approaches are used. 
This dissertation focuses on the poorly understood ATP Binding Cassette subfamily C 
member 2 (ABCC2) transporter, a member of the ATP Binding Cassette family (ABC). 
ABC transporters control the movement of endogenous/exogenous molecules across 
membranes, and can have an important role in defining drug pharmacokinetics.  
ABCC2 is expressed at important pharmacological barriers. It is localised, for example, 
in the basolateral membranes of hepatocytes where it has a critical role in the biliary 
elimination of conjugated metabolites. In addition, it has been suggested that ABCC2 
is responsible for the increase of multidrug resistance in cancer cells, promoting the 
efflux of chemotherapeutic agents. Thus, inhibitors of ABCC2 might be used to 
overcome multidrug resistance. Early predictions of ABCC2 interaction with 
investigational drugs would be beneficial to predict drug pharmacokinetics and the 
possibility of drug-drug interactions.  
The ABCC2 project results in two peer-review publication (referred as Publication I 
and Publication II). In both publication the identification and discussion of probe-
dependent modulators is presented. In Publication II, screening results identified novel 
low µM inhibitors and predictive models were built able to discriminate inhibitors 
from inactive molecules. Further characterization of the structure-activity relationship 
of ABCC2 inhibitors is presented in the Additional Unpublished results. 
α2-adrenoceptors are G protein-coupled receptors, humans and other mammalian 
species have three α2-adrenoceptors subtypes that share a high structural similarity, 
especially in the transmembrane regions. The overall focus of the α2-adrenoceptor 
studies is the design/discovery of low molecular weight molecules able to discriminate 
α2-adrenoceptor from other G protein-coupled receptors as well as among the three 
human subtypes (i.e. subtype-selective molecules), to be used as therapeutic molecules 
with low side effects. Current clinically available α2-adrenoceptors drugs have only 
marginal subtype specificity, which limits the therapeutic usefulness due to side 
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effects. Selective molecule could be used in treating high blood pressure, in the 
alleviation of withdrawal symptoms, and as anaesthetic with fewer side effects than the 
current drugs.  
Two studies on α2-adrenoceptor subtypes are presented in this dissertation (Publication 
III and IV). The experimental part of these studies was conducted by the collaborators 
before my involvement in the projects. Consequently, my part in this work is purely 
retrospective, ie. data analysis. The focus of Publication III was to define the 
involvement of first transmembrane helix in the binding of a series of antagonist. In 
Publication IV, the aim was to identify new α2-adrenoceptors subtype selective ligands. 
Review of literature 
 
 
3 
 
2. Review of literature 
2.1. Membrane proteins 
Cell membranes are heterogeneous assemblies of lipids, proteins and carbohydrates 
that form an approximately 35Å thick layer. Phospholipids, sphingolipids, and sterols 
(like cholesterol) spontaneously organize themselves in a bilayer where the polar heads 
are opposite to each other. The composition of the cell membrane additionally, differs 
between the inner leaflet and the outer leaflet. For example, carbohydrates are involved 
in cell recognition and are normally linked to proteins or lipids only in the outer leaflet 
of the membrane. Membrane proteins can be either interacting only with the surface of 
the membrane (peripheral membrane proteins) or they can be embedded in the bilayer 
(intrinsic membrane proteins).  
Intrinsic membrane proteins mainly have non-polar amino acids pointing towards the 
bilayer, making hydrophobic interactions. The core of the cell membrane is composed 
of the hydrophobic lipid tails and it is approximately 20Å thick, suggesting the need of 
20 amino acids to cross it. To minimize the exposure to the membrane hydrophobic 
core the peptide main chain forms hydrogen bonds and predominantly arranges in α-
helices (White & Wimley 1999).  
Membrane proteins have an essential role in the regulation and control of many 
biochemical pathways and can be classified based on their function as cell surface 
proteins, cell adhesion proteins, cytoskeleton attachment proteins, enzymes, channels, 
transporters, or receptors. 
The ATP Binding Cassette subfamily C member 2 (ABCC2) is a transporter, member 
of the ATP Binding Cassette (ABC) family. Transporters are specialized proteins that 
help the translocation of molecules across the cell membranes. Passive transport, 
occurs when the translocation does not directly require chemical energy, as the 
transported molecules follow their concentration gradient. Active transport instead 
requires energy to transport molecules across the bilayer; in the case of ABC 
transporters the energy source is the hydrolysis of ATP. Additionally, transporters can 
be divided into importers and exporters, depending on the directionality of the 
transport. The largest family of human efflux transporters is the ATP binding cassette 
family (ABC) (Dean et al. 2001a). More than 400 transporters have been identified in 
the human genome that are likely to be associated with pharmacokinetics and safety 
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profiles for drugs (Giacomini et al. 2010). Genetic variants of these membrane 
transporters are known to cause serious metabolic disorders (e.g. cystic fibrosis) 
(Gottesman & Ambudkar 2001) 
α2-adrenoceptors are G protein-coupled receptors (GPCR) that bind adrenaline and 
noradrenaline. GPCRs are intrinsic membrane receptors that recognise different 
extracellular signals such as the variation in the concentration of ions, glucose, oxygen, 
or light and convert it into an intracellular signal. It has been proposed that more than 
60% of current drug targets are membrane proteins located at the cell-surface, with the 
GPCR as the largest family (Overington et al. 2006). Many polymorphisms of GPCRs 
have been identified, showing mutations in coding and no-coding variants (Rana et al. 
2001). Mutant GPCR genes and proteins are associated with several clinical 
conditions, reviewed in Schöneberg et al. 2004. For example, mutation on the gene that 
codes for the arginine vasopressin receptor 2 (AVPR2) has shown to cause 
nephorogenic diabetes insipidus (Knoers 1993). Additionally, mutations can alter the 
binding site of the receptor, modify its signalling, alter the expression levels, or even 
modify the ratio between the inactive and the active population of receptors 
(Thompson et al. 2005; Spiegel 1996; Zalewska et al. 2014).  
2.1.1. Challenges in the study of membrane proteins 
Functional and biochemical studies on membrane proteins are challenging due to 
relatively hydrophobic surface and unstable nature of membrane proteins. For the most 
part, membrane proteins are not expressed in high concentration in native cell 
membranes; therefore, overexpression is needed for functional and structural studies. 
The optimization of the overexpression process is crucial. Many different expression 
systems are used that differ in the post-translational modifications, protein yield, and 
stability. The different expression systems, solubilisation, and purification methods for 
membrane proteins have been discussed in Junge et al. 2008 and will not be discussed 
further here.  
Proteins have to be correctly folded to be functional and membrane proteins can fold 
correctly only if targeted into the cell membrane. This process is controlled by specific 
machinery (translocon) that is encoded by a characteristic sequence of amino acids 
(von Heijne 2006). In addition, the function of the protein is influenced by the 
composition of the membrane, since there are many interactions between the lipids and 
the embedded protein. Many techniques do not allow the study and analyse of proteins 
in such lipophilic and diverse environment, thus proteins have to be extracted and 
studied in detergent or specific lipid settings (Seddon et al. 2004).  
Review of literature 
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2.1.2. Prediction of membrane protein structure  
While in the last years major developments have been made to improve membrane 
protein crystallization, only less than 3% of crystallized proteins are membrane 
proteins (Berman et al. 2000). Therefore, several predictive tools for membrane protein 
structure have been developed.  
Protein structure prediction has developed intensively beginning in 1970’s (Frishman 
2010). The simplest methods predict the amino acids that belong to transmembrane 
segments utilizing hydropathy plots and hydrophobic moment plots (Kyte & Doolittle 
1982). More modern methods have been implemented that use, for example, machine 
learning algorithms and hidden Markov models (e.g. transmembrane hidden Markov 
model TMHMM) (Tusnády & Simon 2001). Additionally, it is possible to predict the 
orientation of the protein identifying the intracellular and extracellular regions, using 
the positive inside rule. The positive inside rule states that a net positive balance, due 
to positively charged amino acids, is found predominantly intracellularly (von Heijne 
& Gavel 1988).  
In addition to the hydrophobicity, it has been shown by multiple alignments that the 
inner core of the protein is more conserved than the periphery. Such information has 
proven to be a very useful tool to indicate the protein interior (Samatey et al. 1995). In 
addition, new programs have emerged that incorporate experimental results such as the 
known location of N-terminus or C-terminus, with a further increase of 10% the 
prediction accuracy (Tusnády & Simon 2001). Prediction of membrane protein 
topology based on the amino acid sequence is reviewed  by Casadio et al. 2003. 
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2.2. Protein-ligand binding 
2.2.1. Protein-ligand equilibrium 
The interaction between a ligand and a protein can be represented as follows (Eq. 1), 
where k1 is the association rate constant and k-1 is the dissociation rate constant. 
Protein (P) + Ligand (L) 
 
Protein-Ligand (PL) Eq. 1 
At equilibrium, following the law of mass action, the affinity between a protein and its 
ligand can be represented by the dissociation constant Kd and its reciprocal is the 
association constant Ka (Eq. 2). 
𝐾𝑑 =
𝑘−1
𝑘1
=
[𝑃][𝐿]
[𝑃𝐿]
=  
1
𝐾𝑎
    Eq. 2 
The total number of binding sites (Bmax) is given by the sum of all occupied and 
unoccupied sites (Eq. 3). 
Bmax = P + PL      Eq. 3 
Then, Kd can be rewritten (Eq. 4). 
 Kd =  L (Bmax - PL) / PL                             Eq. 4 
 
2.2.2. Gibbs free energy 
At equilibrium, the change in free energy of the system is represented as the change in 
Gibbs free energy (ΔG) and expressed as KJ/mol. ΔG is directly proportional to the 
affinity between the protein and the ligand (Kd), the temperature (T), and the ideal gas 
constant (R). Additionally, the energy of binding can be represented as the change in 
enthalpy (ΔH) and the change in entropy (ΔS) at a certain temperature (Eq. 5).  
ΔG =  RT In 𝐾𝑑  =  −RT In𝐾𝑎 =  ΔH −  T ΔS      Eq. 5 
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A spontaneous reaction occurs if the energy of the system decreases, thus having a 
negative ΔG. The enthalpy parameter represents approximately the strength and 
specificity of the molecular interaction between ligand and protein that will be further 
discussed in 2.2.4. Entropy, instead, represents the disorder of the system; this 
parameter is connected to the loss of translational and rotational degrees of freedom of 
both partners (protein as well as ligand). Desolvation and solvent-reorganization 
contribute to both the enthalpy and entropy of binding.  
2.2.3. Theories of ligand binding 
The first theory about ligand binding, the lock and key theory, was proposed in 1894 by 
the German chemist, Emil Fischer. An updated model presented in 1958 by biochemist 
Daniel E. Koshland, Jr. suggested the induced fit theory, where both ligand and protein 
adapt to each other when interacting. This model suggests that the binding interaction 
is not static but dynamic process, where both ligand and protein rearrange to interact 
with each other.   
These models are based on the existence of a primary site, the orthosteric site, which 
binds the endogenous ligand, and after binding, produces a biological effect. Besides 
the orthosteric site, molecules can binding to a topographically distinct sites called 
allosteric sites. Molecules that bind to the allosteric site(s) can enhance or inhibit the 
binding of the endogenous ligand to the orthosteric site (in the case of an enzyme, the 
catalytic activity also can be affected). Allostery is mediated through conformational 
changes that happen within a protein (from one site to another) or can be transferred to 
the neighbouring protein when it occurs in oligomeric protein complexes (Crick & 
Wyman 2013; Monod et al. 1965).  
GPCRs are naturally allosteric proteins as they possess more than one binding site 
topographically separated (Bouvier 2001). The G-protein (coupled to the receptor) is in 
fact the best-known allosteric modulator of GPCR agonist binding (Christopoulos & 
Kenakin 2002; May et al. 2010). In addition, protein-protein interaction between 
GPCRs (homo- and hetero-dimers) and a variety of other proteins, confirm the 
allosteric nature of GPCRs (reviewed in Brady & Limbird 2002). 
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2.2.4. Molecular interactions 
The most common interaction between ligands and proteins are covalent, electrostatic, 
Van der Waals, hydrogen bond, and π-interactions. 
 Covalent 
Covalent interactions, which involve the share of electrons, are the most stable 
chemical interaction between two atoms. Covalent interaction are associated with 
safety and toxicity concerns due to the long duration of action (Mah et al. 2014). When 
an inhibitor is covalently bound to an enzyme, the duration of the interaction maybe be 
so long that it may be impossible to reverse, for example in case of overdose. Of the 
marketed drugs that act on enzymes, about 30% of them act through covalent 
interaction (Robertson 2005). 
 Electrostatic  
Electrostatic interactions occur between two atoms that have an electrostatic charge 
(cation or anion) and can be of attractive or repulsive nature.  An attractive force, 
between two atoms with opposite net charge (negative/positive), is considered here 
(Eq. 6). The interacting force (F) depends on the charges (q1, q2), the square of the 
distance (r
2
), and the dielectric constant (Kε) that can change depending on the 
environment. The dielectric constant is about ~80 in water and usually lower in 
proteins (about four inside a receptor’s hydrophobic binding pocket) (Rubinstein & 
Sherman 2004). 
F =  (Kε)
(𝑞1∗𝑞2)
𝑟2
    Eq. 6 
 Van der Waals  
Van der Waals interactions are a rather weak type of interaction that occur between 
dipoles and induced dipoles. A dipole is by definition a partial charge that is not 
uniformly distributed over the molecule. Dipoles can be permanent or transient in time: 
instant or induced. Instant dipoles occur when electrons are temporarily concentrated 
on one part of the molecule. A molecule with a permanent dipole or charge can affect 
another molecules’ electron cloud and induce a dipole moment. Examples of the most 
common Van der Waals interactions are presented in Figure 1. 
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Ion-dipole 
 
 
 
 
Dipole-dipole 
 
Ion-induced dipole 
 
 
Dipole-induced 
dipole 
 
 
 
Induced dipole-induced dipole  
(or London force/ dispersion) 
 
 
Figure 1 The most common Van der Waals interactions. In red oxygen atoms, in light blue hydrogens, 
in green chlorine atoms and in grey carbons. 
 
 Hydrogen bonds  
Hydrogen bonds are weak interactions that are grouped independently since they 
cannot be explained by Van der Waals interactions, as they have a partial covalent 
component. Hydrogen bonds take place between an electronegative atom and a 
hydrogen atom covalently bound to a second electronegative atom. Intermolecular 
hydrogen bonds are responsible for the high boiling point of water when compared to 
other small molecule hydrocarbons. Water molecules can be both hydrogen bond 
acceptors and hydrogen bond donors. A water molecule acts as a hydrogen bond 
acceptor when its oxygen acts as the electronegative counterpart for the interaction and 
acts as a hydrogen bond donor when the hydrogen is involved in the bond. 
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 π-interactions  
Ligand-protein interaction can be additionally stabilized with interactions that involve 
π-systems, the most common ones are cation-π, π-π and C/N/OH-π that are presented 
in Figure 2. π-systems are conjugated systems that occur when p-orbitals (p molecular 
orbitals) overlap and π-electrons can be delocalised in the conjugated system. In the 
case of aromatic rings, it creates an electron-rich system over and under the aromatic 
ring and an electron-poor region at the level planar to the ring. 
Cation - π 
 
π - π 
 
OH - π 
 
Figure 2 An example of π-interactions. 
2.2.5. Transport kinetics 
Transport kinetics can be described by analogy to the enzyme kinetic models initially 
proposed by Leonor Michaelis and Maud Menten in 1913 (original paper has been 
translated in English by Johnson & Goody 2011). The main difference between 
enzymes and transporters is that enzymes break and form new bonds in substrate 
molecules, while transporters translocate their substrate(s) across the membrane. 
Formally the efflux transport can be described as following (Eq. 7), with T1 
representing the inward facing conformation and T2 the outward facing conformation. 
In the case of active transport, the transport cycle (the conversion between T1 and T2 
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and vice versa) is energy dependent. Specifics of ABC transporters are presented in 
section 2.3.1 in the Alternative access model paragraph.  
 
Eq. 7 
The first assumption of the Michaelis-Menten enzyme kinetic model is that at the 
steady state, the concentration of the enzyme-substrate complex is constant over time 
and independent of the concentration of the substrate. This happens only when the 
concentration of substrate is so high that all the enzymes are saturated, thus a further 
increase of substrate will not change the rate of catalysis. In this condition of high 
substrate concentration, it is possible to identify a plateau, where the rate of reaction is 
constant, described as Vmax (Figure 3). The second assumption is that the reaction 
proceeds only to one product; hence, the equilibrium is shifted to the right. When all 
these assumptions are in place, it is possible to plot the variation of the reaction rate 
against the variation of the substrate concentration (Figure 3) and calculate the reaction 
rate with the Michaelis-Menten equation (Eq. 8). Where Km is the concentration of the 
substrate when the rate of reaction is half of the maximal rate, Vmax, the Km parameter 
is used to compare the binding affinity of different substrates; a lower value of Km 
indicates that a lower concentration of substrate is needed to reach half of the 
maximum rate.  
 
Figure 3 Michaelis-Menten kinetics. Variation of the reaction rate is plotted against the increase of 
substrate concentration. Vmax  is the maximum rate of enzyme catalysis; Km concentration of the substrate 
at half of Vmax. 
k -1 
k 1 
T1  +  S 
k -2 
k 2 
T1S T2S 
k 3 
T2  +  S 
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Activity =
𝑉𝑚𝑎𝑥∗S
𝐾𝑚+𝑆
        Eq. 8 
Similar to enzymes, transporters are proposed to have a main substrate binding site that 
can be saturated and inhibited and, therefore, the mechanism of transport can be 
represented with Michalis-Menten kinetics (Bentz et al. 2005).  
At the steady state (Eq. 7), the transporter substrate complexes (T1S and T2S) are 
considered equivalent. The rate of transport (J) is measured as the function of the 
translocation of the substrate. Similar to enzymes, at high concentration, the rate 
capacity approaches Jmax; thus, the rate of the transport can then be calculated with the 
Michaelis-Menten equation (Eq. 9). As with enzymes, Kt is the concentration of the 
substrate at half of the maximal transport rate. 
J =
𝐽𝑚𝑎𝑥∗S
𝐾𝑡+𝑆
    Eq. 9 
Additionally, for transporters it is possible to calculate the unitary turnover rate (Rt) 
that is defined as the number of molecules transported across the membrane in the 
unity of time. It represents how fast the transporter cycles occur, normally expressed as 
cycles per second and is calculated (in Eq. 10) with Bmax as the total amount of 
transporters. 
𝑅𝑡 =  
𝐽𝑚𝑎𝑥
𝐵𝑚𝑎𝑥
               Eq. 10 
In the case of transporters it is important to define two groups of interacting ligands, 
transported molecules (substrates) or non-transported ligands. 
2.2.6. Two-state receptor theory 
Receptors are specialized proteins that convert extracellular information into an 
intracellular signal. The classic two state receptor theory proposed in 1965 describes 
the interaction between ligands and receptors on a molecular level. Ligand binding to 
the receptor changes the conformation of the receptor from the inactive (R) to the 
active (R*) conformation (Monod et al. 1965). This assumes that equilibrium between 
the active and the inactive conformation exists (Eq. 11). In addition, receptors may 
signal in the absence of a ligand, suggesting a spontaneous conversion between R and 
R*.  
R R*                  Eq. 11 
Review of literature 
 
 
13 
 
When ligands bind, two are the possibilities that may coexist. The conformational 
selection theory proposes the ligand to stabilize one or the other conformation, shifting 
the equilibrium between the two forms. The conformational induction theory instead 
suggests that the ligand actively promotes the conformational change between the two 
conformations. At the moment, it is not possible to validate or invalidate one or the 
other theory experimentally. In addition, it has been proposed that not only receptors 
can interconvert between the two states R and R* but can include some intermediate 
transitions stages (Park et al. 2008). 
The propensity of the drug to bind to the receptor is called affinity, it is normally 
calculated as IC50 or Ki; while, the extent of the functional changes imparted by the 
receptor are called efficacy.  
Full agonists are ligands that, after all the receptors are occupied, can promote the 
maximal response to be reached (full efficacy is reached). Partial agonists, instead are 
ligands that produce less than the full effect even at saturation; thus acting like an 
antagonist in the presence of a full agonist (blocking the full effect).  
An inverse agonist, instead, imparts the opposite effect than the agonist, stabilizing the 
inactive conformation of the receptors (R), thus shifting the equilibrium to the left (Eq. 
11). This shift of the equilibrium can lower the baseline activity to null or, in some 
cases, even cause inverse activity of the receptor. Neutral antagonist are by definition 
ligands able to bind to both R and R*, preventing any agonist response but not altering 
the equilibrium between R and R* and not changing the baseline activity (Figure 4). 
After the identification of constitutively active receptors, many ligands initially 
identified as antagonist, with a negative efficacies, have been later reclassified as 
inverse agonist (Gilchrist 2007). 
Review of literature 
 
 
14 
 
 
Figure 4 Dose response curves. The variation of the observed activity of the receptor plotted against the 
increase of the concentration of different ligands. The increase of the concentration of the agonist will 
fully activate the receptor (reaching full response at saturation). Partial agonists instead, even at saturation, 
are not able to fully activate the receptor. Antagonists do not alter the base line activity of the receptor 
(neither increasing nor decreasing). An inverse agonist at saturation can block fully the receptor activity, 
like in this case eliminating even the base line activity. 
For GPCRs, it has been recognized that many may be constitutively active, able to 
signal in the absence of a bonded ligand confirmed in endogenous systems (Tiberi & 
Caron 1994). In addition, a tertiary model can be proposed where the receptor is in 
equilibrium with the G-protein and the cubic ternary model that includes an allosteric 
modulator (Figure 5). 
 
Figure 5 Tertiary model and cubic tertiary model. On the left the tertiary model and on the right the 
cubic tertiary model. Agonist (A), receptor (R), G-protein (G) and activated conformation (*).  
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2.3. ABC transporters 
2.3.1. ATP binding cassette family 
The ATP binding cassette (ABC) systems are one of the most ancient protein families, 
representatives of such family can be found in both prokaryotic and eukaryotic cells 
(reviewed in Rees et al. 2009). ABC transporters are able to carry across the membrane 
a diverse range of molecules, from small ionic compounds to very hydrophobic 
molecules. Functional transporters consist of two transmembrane domains (TMD) and 
two nucleotide binding domains (NBD). Some transporters are expressed as fully 
functional proteins containing two NBD and two TMD, e.g ABCB1; or as half 
transporters with one NBD and one TMD that need to dimerize to be fully functional 
e.g. ABCG2    
The transmembrane domains (TMDs), which are less conserved than nucleotide 
binding domains (NBD), are responsible for binding and translocation of the substrates 
across the membrane. These TMDs are not present in all human members of the family  
and some members of the ABC family are most probably not transporters (Dean et al. 
2001a). 
The nucleotide binding domain (NBD) is a highly conserved domain that binds and 
creates the catalytic site for the ATP hydrolysis. Several conserved motifs can be 
identified: the walker A (GXXGXGKS/T), the walker B (ΦΦΦΦD, Φ is a hydrophobic 
residue), and the signature motive C (LSGGQ) that are specific for the ABC 
transporters (Schmitt et al. 2003). Additionally, three conserved loops that are 
important for the catalytic function can be identified: the A loop (an aromatic loop 
normally containing at least one tyrosine), the D loop (with a conserved SALD motif), 
the Q loop (composed of about eight amino acids including a conserved asparagine), 
and the H loop or switch region (present in the C-terminal part of the domain with a 
conserved histidine) (ter Beek et al. 2014).  
 Classification 
In humans, 48 ABC efflux transporters have been classified based on the phylogenetic 
analysis of NBD into seven families (A-G) (Dean et al. 2001a).  
The ABCA subfamily is composed of 12 proteins that regulate the homeostasis of 
cholesterol and lipids (Kaminski et al. 2006). It has been demonstrated that the 
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mutation on ABCA1 can cause the Tangier disease characterized by the accumulation 
of cholesterol in many tissues (Brooks-Wilson et al. 1999).  
The second subfamily, the ABCB it is even called the multidrug resistant (MDR) 
family as many members of this family cause multidrug resistance. This subfamily is 
composed of four full transporters and seven half transporters. The ABCB subfamily is 
known to transport a wide range of generally hydrophobic molecules (Dean et al. 
2001b). The best characterised transporter of the subfamily is ABCB1 commonly 
known as MDR1 or P-gp (Palmeira et al. 2012).  
The third subfamily, ABCC, is also known as the multidrug resistant associated 
proteins (MRP) family as nine of its members confer multidrug resistance. The cystic 
fibrosis gene (CFTR, ABCC7) is an important transporter in the subfamily; inborn 
mutations of these gene have shown to cause cystic fibrosis (Gottesman & Ambudkar 
2001).  
The ABCD subfamily is composed of four members encoded as half transporters 
functioning as homo- or hetero-dimer, and are known to transport very long fatty acids-
CoA (Kemp et al. 2011). Mutations of the ABCD1 are linked X-linked 
adrenoleukodystrophy (Mosser et al. 1993).  
The ABCE subfamily is composed of a single protein (also known as ribonuclease-L 
inhibitor) expressed as a single NBD, without any TMD, thus unlikely to function as a 
transporter (Karcher et al. 2008). ABCE is suggested to promote interferon activity 
(Bisbal et al. 1995).  
Three proteins are grouped in the ABCF subfamily, as well as the ABCE are expressed 
without a TMD, thus not functioning as transporter. It has been proposed that they 
could be involved in ribosome biogenesis or protein synthesis (Dong et al. 2005; 
Tyzack et al. 2000).  
The white or ABCG subfamily of ABC transports is composed of five members 
encoded as reverse half transporters and are known to transport lipids and sterols 
(Wang et al. 2013). ABCG1 and ABCG4 mediate the transport of cholesterol and high 
density lipoproteins (Wang et al. 2004).While the most characterized protein in this 
family is the BCRP or ABCG2 known also as breast cancer resistant protein (BCRP) 
shown to be expressed in choriocarcinoma cell lines (Bailey-Dell et al. 2001). 
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 Transporters and pharmacokinetics 
ABC transporters have a central role in secretory epithelia to excrete endogenous 
metabolites, for example bile salts or bilirubine glucuronides. An important 
consequence of the presence of efflux transporters in healthy tissues is their impact on 
pharmacokinetics, i.e. the absorption, distribution and elimination, of many drugs 
(Cascorbi 2006). For instance, the bioavailability of orally administered substrate drugs 
is regulated by efflux transporters expressed in intestinal epithelial cells. Additionally, 
at the blood-brain barrier efflux transporters impede the penetration of drugs into the 
brain, thereby decreasing the efficacy of treatment directed at the central nervous 
system, inhibitors in this case could improve drug therapy (Schinkel et al. 1996).  
Efflux transporters have been found to be important mediators of drug-drug 
interactions that may lead to serious adverse reactions. Drug-drug interactions (DDI) 
are caused by a drug molecule that induces or inhibits a metabolic enzyme, or in this 
case, a transporter thereby influencing the interactions of the protein with another drug. 
DDIs can promote or decrease the metabolism or transport of the victim drug and can  
cause drug induced toxicity or alter the efficacy of drug treatment (Keogh 2012; El-
Sheikh 2007). For example, inhibition of efflux transporters in the intestine can lead to 
several-fold increase in the bioavailability of a victim drug. The bioavailability of 
irinotecan is increased up to a five-fold when an efflux transporter inhibitor, verapamil, 
is co-administered (Bansal et al. 2009). 
 Multidrug Resistance 
Multidrug resistance (MDR) is a general phenotype in which a human tumour becomes 
resistant to multiple chemotherapeutic drugs. Drug resistance is one of the main 
reasons of failures in cancer chemotherapy. The overexpression of ABC transporters in 
cancer cells can limit the accumulation of the chemotherapeutic drug in the cells, thus 
causing the cells to become resistant to the drug. 
For instance, a clear association of high MDR1 expression in leukemic cells and poor 
outcome has been demonstrated and therefore inhibitors of MDR1 have been evaluated 
in clinical trials for chemotherapeutic treatment of acute myeloid leukemia. 
Unfortunately, the MDR1 inhibitors have not been able to improve the therapeutic 
outcome (Shaffer et al. 2012). 
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 Aternative access model with a twist  
The alternate access mechanism of transport was initially proposed in 1966 by 
Jardetzky for membrane pumps, suggesting the presence of a central binding cavity 
(orthosteric site) that is never simultaneously open to both sides of the membrane 
(Jardetzky 1966). This suggests that the transporter switches from an inward to an 
outward conformation.  
The presence of these two conformations, suggested by Jardetzky, is in agreement with 
the solved 3D structures of the ABC transporters. The first full length ABC exporter 
(Sav1866) was crystallized in 2006 in the outward open conformation with ADP or 
ATP analogues (AMP-PNP) (Dawson & Locher 2006, 2007). The first nucleotide-free 
inward open conformation of mouse mdr1 was solved three years later by Aller et al. 
2009 and later refined (Li et al. 2014). Additional insight in the mechanism of transport 
followed, after the low resolution crystal structure of the Lipid A ATP-
binding/permease protein (MsbA) lipid flippase from Salmonella typhimurium (Ward 
et al. 2007). Here the “alternative access model with a twist” was proposed, in which 
the conformational changes to propagate from the NBDs and involve a twist of about 
30° of the helices in the TMDs (Ward et al. 2007). The first high resolution (2.9Å) 
heterodimeric protein (TM287 and TM288) from Termogota maritma showed an 
inward facing conformation with only partially separated NBDs (inward-closed) (Hohl 
et al. 2012). Recently, an additional intermediate conformation was crystallized, filling 
the gap between the different conformations and increasing our current knowledge of 
the mechanism of transport for ABC exporters  (Choudhury et al. 2014).  
It has been proposed that two ATP molecules are needed for the translocation of the 
substrate (Senior et al. 1995). Two alternative models have been suggested to define 
the energy stroke that promotes the drug from the high affinity site (T1) to the low 
affinity site (T2) (Eq. 7, section 2.2.5). The first model proposes that the substrate and 
the ATP initially bind to the transporter simultaneously and a first hydrolysis is needed 
for the efflux and the second one to restore the ground state (Sauna & Ambudkar 
2000). The second model, postulates that the formation of the NBD dimer is a result of 
the conformational changes occurring after substrate binding and the two consequent 
hydrolysis events are needed to restore the transporter in the initial state (Higgins & 
Linton 2004). Additional studies are needed as it is not possible to validate or 
invalidate one or the other model experimentally. 
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Briefly, combining the information obtained from the crystal structures it is possible to 
propose the efflux transport cycle (Choudhury et al. 2014). Starting from an inward-
open conformation, where substrate binding occurs, conformation changes occur so 
that the transporter rearranges to an inward-closed conformation. Consequently, 
additional rearrangements bring the transporter to an outward-open conformation 
where the substrate can be released. After the release the outward conformation closes, 
outward-occluded, and additional conformation changes restore the transporter to the 
initial inward conformation (Figure 6). 
 
Figure 6 The proposed ABC efflux transport mechanism. This proposed mechanism is explained using 
the different high resolution ABC efflux crystal structures, crystalized in different conformations. 
Conformation and pdb codes are in bold. Substrate is represented as yellow rhombus; TMD1 and NBD1 in 
magenta and light pink respectively while TMD2 and NDB2 in teal and light teal. 4M2S (Aller et al. 2009; 
Li et al. 2014); 3QF4 (Hohl et al. 2012), 2ONJ (Dawson & Locher 2006; Dawson & Locher 2007) and 
4PL0 (Choudhury et al. 2014). The arrows represent the steps in the direction of the transport process. The 
Figure is adapted from Choudhury et al. 2014. 
ABC efflux transporters’ binding sites are still weakly characterized, as no crystal 
structure with a transported substrate is available. Most likely the binding cavity is 
located in the interface of the two TMDs as shown in the refined crystal structure of 
mouse mdr1, crystallized with two inhibitors (QZR9-R RR or two QZR9-SSS), and 
showing a partial overlap of the binding site (Aller et al. 2009; Li et al. 2014).  
Pharmacological evidence suggests the presence of two substrates binding site in 
MDR1, the hoechst and the rhodamine site (Parveen et al. 2011; Shapiro & Ling 1997). 
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2.3.2. Multidrug resistance associated protein 2 
ABCC2 or multidrug resistance associated protein 2 (MRP2) is classified into the 
ABCC family (Dean et al. 2001a). The ABCC family is composed of twelve full 
transporters: nine of which are multidrug resistance associated proteins (MRP), two 
sulfonylurea receptors (SUR), and the cystic fibrosis transmembrane conductance 
regulator (CFTR). 
 Stucture 
ABCC2 is a 1545 amino acid protein arranged in 17 transmembrane helices and two 
homologous intracellular NBDs that bind ATP. The 17 transmembrane helices can be 
grouped into three transmembrane domains, two homologous domains that constitute 
the translocation pathway (TMD1 and TMD2), and TMD0, which function is still for a 
large part unknown (Figure 7). 
 
Figure 7 The ABCC2 topology. ABCC2 consists of 1545 amino acids that are organized in three TMDs 
and two NBDs. Two glycosylation sites are present in the N-terminus and one in the TMD2. The figure 
was generated using Protter (Omasits et al. 2014 ) and then modified. 
The N-terminal part and TMD0 are proposed to be involved in the correct apical 
localisation of the transporter in the cell membrane and not important for the 
translocation of a few tested substrates (Bakos et al. 1996). Swaps between the TMD0s 
of ABCC2 and ABCC1, a homologous protein that is localized at the basolateral side 
of polarized membranes, showed that ABCC2-TMD0 is responsible for the apical 
localisation of the protein and/or stabilizes it into the membrane (Mateus et al. 2002; 
Konno et al. 2003). Glycosylation at the N-terminus, at amino acids 7 and 12, has also 
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been suggested to be important in targeting the protein to the apical membrane (Mateus 
Fernández et al. 2002).  
Similarly to MDR1, the pharmacological characterization of ABCC2 showed two 
different binding sites. Initially it was proposed that ABCC2 could have two drug 
binding sites, one with high affinity to glutathione (GSH) (G-site) and one with low 
affinity to GSH and high for drugs (D-site) (Evers et al. 2000). This model have been 
later revised in a substrate binding site (S-site) and a modulator site (M-site), 
suggesting that compounds binding to the M-site are not transported but affect the 
transport of the compounds situated in S-site simulates (Zelcer et al. 2003). Inhibitors 
of the efflux transporters can thus either compete for binding with the substrate or bind 
to a separate modulator site.  
 Function 
ABC transporters have an important role in drug absorption, distribution, elimination, 
and drug safety. ABCC2 is expressed in several organs (liver, kidney, and placenta) at 
the apical side of polarized cells. Initially, ABCC2 has been named the canalicular 
multi-specific organic anion transporter 1 (cMOAT1) due to its expression at the 
canalicular membranes of hepatocytes.  
Several functional polymorphisms have been identified, but only a small amount of 
them lead to a non-functional transporter, causing the Dubin-Johnson syndrome. The 
Dubin-Johnson syndrome is characterized by the accumulation of bilirubin and 
conjugated bilirubin in the hepatic cells instead of elimination to the bile (Nies & 
Keppler 2007).  
ABCC2 has a broad substrate specificity, transporting across the cell membrane 
compounds of very diverse structure (Pedersen et al. 2008). Metabolic conjugates are 
known to be endogenous ABCC2 substrates, these include leukotriene C4, estradiol 
glucuronide,  bilirubine glucuronide, and estrone-3-sulphate (Leier et al. 2000; 
Paulusma et al. 1999; Cui et al. 1999; Hagmann et al. 1999; Kamisako et al. 1999).  In 
addition, to the endogenous compounds, ABCC2 effluxes exogenous compounds, 
preventing their toxic accumulation in the cell (reviewed in (van der Schoor et al. 
2015). Examples of these molecules are cisplatin, paclitaxel, docetaxel, vinblastine, 
erythromycin indinavir, ritonavir, and saquinavir (Cui et al. 1999; Huisman et al. 2005; 
Evers et al. 2000; Agnani et al. 2011; Huisman et al. 2002).  
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 ABCC2 mediated drug-drug interaction 
Clear evidence of ABCC2 involvement in DDIs has not been presented yet, however, it 
is plausible that hepatotoxicity may be the result of compounds that inhibit ABCC2 
and other transporters of the same family (ABCC3, ABCC4, and ABCC5). At the last 
international transporter consortium meeting (2013), it has been suggested to  
investigate ABCC2-mediated interactions if drug-induced hyperbilirubinemia is 
observed (Hillgren et al. 2013). Currently, regulatory agencies in the US and Europe 
are advising to study transporter mediated DDI defining the interaction between two 
ABC transporters (ABCB1 and ABCG) and new investigational drugs (European 
Medicines Agency 2013; FDA 2012). 
Several in-vitro systems are used to study the interplay of ABCC2 transporter and 
drugs, to define drug interaction; the most used ones are based on primary cells lines, 
recombinant cell line, and plasma vesicles. 
Primary cell lines and immortalized cells are used mainly for qualitative studies and to 
understand mainly the interplay of human transporters (Schrenk et al. 2001). For 
example, hepatocytes (plated, in suspension or sandwiched) are used to evaluate 
hepatic uptake and efflux as these cell lines allow the interplay of many transporters. 
From such systems it is possible to calculate the efflux ratio and intrinsic permeability 
that have shown to closely relate to the in-vivo ones (Polli et al. 2001; Lumen et al. 
2010).  
Recombinant cell lines, instead, tend to be more robust and reproducible systems and 
are cultured as polarized monolayers. Oocytes are considered the purest tool to study 
ABC transporters and are grown in semi permeable supports that allows measurements 
of the drug in both apical (A>B) and basolateral (B>A) direction. The measurement on 
both sides of the cell layer is important to understand the impact of passive 
permeability and can be used to assess the interplay between uptake and efflux 
(Brouwer et al. 2013). The major pitfall of cell-based systems is the low high 
throughput and the difficulty in maintenance, thus isolated plasma vesicles are used 
more.  
With plasma vesicles it is possible to study the transport of labelled substrates and the 
modulation of transported probes. The vesicular transport assay will be further 
discussed in material and methods paragraph 4.2.1. Additionally, in-vitro methods have 
been presented in detail in Hillgren et al. 2013. 
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 Multidrug resistance associated protein 
ABCC2 was initially isolated by Taniguki in 1996 from cisplatin resistant cells, thus 
classifying this transporter as a multidrug resistance associated protein (MRP2) 
(Taniguchi et al. 1996). It is still not clear if the overexpression of ABCC2 is the cause 
of multidrug resistance or a mere consequence of the chemotherapy (Borst et al. 1997). 
Nevertheless, ABCC2 modulation has been investigated to evaluate if the co-
administration of ABCC2 inhibitors in chemotherapy is a positive strategy to overcome 
the multidrug resistance. An example of the use of ABCC2 inhibitors to overcome drug 
resistance can be the use of montelukas in cancer therapy. Montelukas is an 
antihistaminic drug that has been identified as a possible/positive adjuvant in 
combination with taxol and sequinavir (Roy et al. 2009). 
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2.4. G protein-coupled receptors 
2.4.1. General features  
G protein-coupled receptors (GPCR) are intrinsic membrane receptors that recognise 
different extracellular signals and convert it into intracellular signals. In humans, 791 
GPCR transcripts have been phylogenetically classified into five different families. 
The A class or rhodopsine like receptors (662, number of receptor in the class) is the 
largest family and further divided based on interacting ligand; α (15) binding peptide or 
amines; β (35) binds peptides; γ (59) binding chemokine, neuropeptides and opioids, 𝛿 
(59) that bind glycoproteins, purine, and olfactory receptors (460) (Fredriksson et al. 
2003). Adrenoceptors are classified in the A-α class, as they bind catecholamines 
(amines).  
GPCRs are composed of seven transmembrane helical segments of about 25-35 amino 
acids, an extracellular N-terminal domain, and an intracellular C-terminal domain. The 
general fold can be seen from the first mammalian structure, bovine rhodopsin 
(Palczewski et al. 2000). Each of the seven helices is characterized by conserved amino 
acids that form the signature of the family (Table 1). 
Table 1 Conserved amino acids in the A- α class. 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 
GxxN LAxxD E/DRY/F W PxxxxxFxY FxxxWxP NP 
Specific nomenclatures for GPCR have been developed. The most used is the 
Ballesteros-Weinstein nomenclature where to the most conserved amino acids in all 
TM is assigned the helix number and the number of .50 (for example conserved 
asparagine in TM1 is assigned 1.50) (Ballesteros & Weinstein 1992). 
 Signal transduction/ downstream pathways 
Signal transduction occurs intracellularly in response to an extracellular signal. A 
ligand binding to a receptor causes a conformational change that activates the 
signalling pathway. In GPCRs, the signalling pathway occurs via GTP proteins (G 
protein) that is coupled with the receptor intracellularly. In the inactive form the G 
protein is a trimer consisting of three subunits α, β, and γ, with the Gα subunit binding 
GDP. After ligand binding, conformational changes of the receptor cause the 
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dissociation of the trimer into Gα (with the exchange of GDP to GTP) and Gβγ that may 
or may not have been pre-coupled. More than 10 homologues of each of Gα, Gβ, and Gγ 
subunits exist, forming various combinations (Clapham et al. 1995). 
The signalling cascade is initiated when the active Gα dissociates from the Gβγ dimer 
and binds with e.g adenylate cyclase, which then leads to the production of a secondary 
messenger like cAMP. Another common secondary messenger is phosphatidylinositol-
2,4-biphosphate and diglycerol that are produced after the activation of phospholipase 
C. The secondary messenger in turn activates the downstream pathway usually related 
to gene expression, often through the activation of a kinase (Pearson et al. 2001). 
Desensitization is an important process that diminishes the receptor response after its 
exposure to a ligand (Katz & Thesleff 1957). The short term desensitization occurs via 
phosphorylation of the intracellular domain by a protein kinase. Phosphorylated GPCR 
bind the β-arrestin, a cytosolic protein, that mediates the internalization of GPCRs and 
desensitization, restoring the G protein complex (Tian et al. 2014). The long-term 
desensitization, instead, occurs through changes in the expression of the receptor and 
other proteins in the pathway (down regulation). 
Additionally, it has been identified that some ligands trigger the β arrestin pathway, 
preferably to the G protein coupled one (Lohse et al. 1990). In addition, many GPCRs 
can couple together as hetero- and homo-dimers, which increases the complexity in G 
protein-coupling even further (Waldhoer et al. 2005). 
 Receptor active-inactive conformation 
Additional evidence of the two state receptor models (presented in section 2.2.6) comes 
from the β2 adrenoceptor crystal structures. The β2 adrenoceptor has been crystalized 
with both an agonist (BI-167107) and with an inverse agonist, (carazolol) (Rasmussen, 
et al. 2011b; Cherezov et al. 2007). Thus, it is possible to appreciate the difference 
between the “active” and an “inactive” conformations, respectivelly (Figure 8) 
(Rasmussen et al. 2011a). 
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Figure 8 β2-adrenoceptor in the active and inactive conformation. In blue β2 adrenoceptor in the 
inactive conformation, with carazolol an inverse agonist pdb code 2HR1; in green β2 adrenoceptor in the 
active conformation with BI-167107, pdb cose 3P0G. Adapted from Rasmussen et al. 2011a. 
The overall root mean square deviation (rmsd) of the two receptor structure is less the 
1Å (Rasmussen et al. 2011a). The largest differences are in the cytoplasmic site of the 
receptors, where TM6 and TM5 moves outward and away from the central core while 
TM7 and TM3 move inward. These movements break the conserved salt bridge 
(known to be important for activation) between D5.50 - R3.49, thus allowing a 
clockwise rotation TM6 of about 11Å. In contrast to the changes in the cytoplasmic 
domain, the changes in the binding pocket are minimal (Rasmussen et al. 2011b). 
2.4.2. α2-adrenoceptors 
Adrenoceptors are GPCRs that bind endogenously adrenaline and noradrenaline (in 
U.S: epinephrine and norepinephrine) (Figure 9). 
Noradrenaline Adrenaline 
 
 
Figure 9 2D structure of noradrenaline and adrenaline. 
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Adrenoceptors are the main mediators of the sympathetic nervous system, regulating 
many physiological functions, such as the increase in heart rate, digestion functions, or 
altering the respiratory rate producing what is known as fight-or-flight responses. 
Adrenoceptors were divided into three main classes α1-, α2-, and β- adrenoceptors by 
Ahlquist in 1948 based on their affinity to different catecholamines and the different 
effect observed in the smooth muscles. A further classification divides the three classes 
in subtypes. Both α1 receptors and β2 receptors are expressed in the vascular system 
and bind to adrenaline and noradrenaline. Vasoconstriction occurs after stimulation of 
the α1 receptor while the vasodilatation is caused by the binding of these 
catecholamines to β2 receptor (Ahles & Engelhardt 2014). 
In humans and mammals, there are three α2-adrenoceptors subtypes: α2A-adrenoceptor, 
α2B-adrenoceptor and α2C-adrenoceptor (Bylund et al. 1992). Based on classical 
physiological functions, α2-adrenoceptors are considered presynaptic receptors that 
regulate, with negative feedback, the additional release or adrenaline or noradrenaline 
(Langer 1974). α2-adrenoceptors mostly coupled with Giα or Goα, inhibit the adenylate 
cyclase causing the reduction of cAMP in the cell, which then activates a receptor-
operated K
+ 
channel and blocks the Ca
2+
 voltage channel (Limbird 1988). Thanks to 
molecular cloning, ligand binding, and anatomical and functional studies, it was 
possible to show that α2-adrenoceptors are also expressed post-synaptically and extra-
synaptically (Perälä et al. 1992; Scheinin et al. 1994).  
The α2A-adrenoceptor is composed of 450 amino acids, the α2B-adrenoceptor of 447, 
and the α2C-adrenoceptor of 462 (Xhaard et al. 2006). The major differences in the 
amino acids composition are present in the N-terminus (differing for the number of 
amino acids 28, 7, and 46 respectively A, B, and C), in the third intracellular loop and 
in the C-terminus (Xhaard et al. 2006). Additionally, the predicted glycosylation sites 
varies as the N-terminus of α2B-adrenoceptor is much shorter than the other subtypes 
and cannot accommodate the two glycosylation sites present in the other receptors. The 
palmoytilations site is an important anchor for the protein to the membrane. This site is 
conserved in both α2A-adrenoceptor and α2B-adrenoceptor but not present in α2C-
adrenoceptor where the cysteine is replaced with a phenylalanine (Figure 10). 
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Figure 10 The α2-adrenoceptors subtypes. The figure was generated using Protter (Omasits et al. 2014 ) 
and then modified. 
The overall sequence identity between the three subtypes (Figure 11). It shows 170 
conserved amino acids that represent the 55%, 59%, and 52% of the full sequence of 
α2A-adrenoceptor, α2B-adrenoceptor, and α2C-adrenoceptor respectively. If considering 
only the amino acids surrounding the binding cavity the conservation is even higher 
with 25 conserved amino acids over the total of 30 (Table 2). 
Table 2 Sequence variation of the amino acids predicted in the binding cavity for the three subtypes. 
In bold font the variable positions. 
Amino acids location in the binding site 
 2.53 2.57 3.25 3.28 3.32 3.33 3.36 3.37 4.52 4.56 4.60 5.38 5.39 5.42 5.43 5.46 
α2A V V C Y D V C T I I P Y I S C S 
α2B V V C Y D V C T I I P Y V S S S 
α2C V V C Y D V C T I I P Y I S C S 
 
Amino acids location in the binding site 
 5.47 6.44 6.48 6.51 6.52 6.55 7.39 7.42 7.43 7.45 xl2.49 xl2.50 xl2.51 xl2.52 
α2A F F W F F Y F G Y N R C E I 
α2B F F W F F Y F G Y N Q C G L 
α2C F F W F F Y F G Y N Q C Q L 
α2-adrenoceptors are localized in both the central nervous system, peripheral nervous 
system, and peripheral tissues (like smooth muscles) (Saunders & Limbird 1999). A 
precise pharmacological function of each subtype is difficult to define, largely due to 
the lack of subtype-selective probes. Anatomical data on expression have been used to 
link specific physiological function of the subtypes. α2A-adrenoceptors and α2C-
adrenoceptors are predominantly expressed in the central nervous system while the 
α2B-adrenoceptor is expressed predominantly in the vasculature. In addition to the 
negative regulation of noradrenaline and adrenaline neurotransmitter feedback, in some 
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cases the α2A-adrenoceptor and α2C-adrenoceptor act as heteroreceptors inhibiting the 
release of other neurotransmitters like dopamine or serotonin (Bücheler et al. 2002; 
Scheibner et al. 2001). They regulate the pain perception (antinociception), sedation 
and hypnosis, behavioural functions (inhibiting the processing of sensory information, 
thus can be used in schizophrenia, post-traumatic stress, attention deific disorder and 
drug withdrawal), and cardiovascular (with a hypotensive and bradicardiac function)  
(Hein 2006). 
 
Figure 11 Alignment of the α2-adrenoceptors subtypes. 
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2.4.3. Deciphering α2-adrenoceptors molecular features 
The pharmacological differences of α2-adrenoceptors subtypes have been difficult to 
elucidate, in fact the majority of the drugs used are not subtype selective and can cause 
important side effect (Gyires et al. 2009).  
In Finland, Juvantia Pharma Ltd discovered several compounds that showed selectivity 
of 1000-fold to the α2C-adrenoceptor and some to the α2B-adrenoceptor (Höglund et al. 
2006). An example is the ligand presented in patent number US6521632B2 an α2B-
adrenoceptor selective, and  fipamezole an α2-adrenoceptor selective antagonist 
(Michel et al. 1990). Fipamezole is currently licenced to Santhera pharmaceuticals and 
succeeded as a drug candidate for the treatment of levodopa-induced dyskinesia in 
Parkinson's disease (Savola et al. 2003).  
Currently dexmedetomidine and guanfacine are new α2-adrenoceptor selective agonist 
but have shown to have also affinity towards other GPCRs (Lee et al. 2013; Lowry & 
Brown 2014; Savola et al. 2003). From the industrial point of view, small molecules 
like medetomidine, an α2-adrenoceptor agonist, has been developed as antifouling and 
used now for its sedative properties as anaesthetic for small animals (Lind et al. 2010). 
In the last 20 years in Finland, much as been done to understand the important residues 
in ligand binding to the α2-adrenoceptors subtypes (Salminen et al. 1999; Nyrönen et 
al. 2001; Peltonen et al. 2003; Xhaard et al. 2005; Laurila et al. 2007). Many different 
techniques, ranging from biophysical/biochemical methods to molecular modelling in 
combination with molecular pharmacology, have been used to map the amino acids 
exposed in the binding pocket of the active (agonist-bound) and inactive (antagonist-
bound) conformations. In particular, covalent binders such as phenoxybenzamine, 
chloroethylclonidine (CEC), and 2-aminoethyl methanethiosulfonate (MTSEA) were 
used in conjunction with receptor constructs bearing engineered cysteines (Frang et al. 
2001; Salminen et al. 1999; Marjamäki et al. 1999).  
As a result, molecular interaction of the catechol ring were identified to be quite 
similar to the ones found in the β2-adrenoceptors bound to isoprenaline; identifying 
hydrogen bonds between the hydroxyl groups of the catechol and with S5.42 and S5.46 
(with meta-OH and para-OH respectively (Peltonen et al. 2003; Xhaard et al. 2006). 
Additionally, it was suggested the β-hydroxyl of the aspartate D3.32 is responsible for 
an additional hydrogen bond with the R-enantiomers (Nyrönen et al. 2001). With the 
use of docking simulation seven additional interactions were predicted to be important 
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for agonist binding to the α2-adrenoceptors: V3.33, T3.37, C5.43, F5.47, Y6.55, F7.38, 
and F7.39 (Nyrönen et al. 2001; Peltonen et al. 2003). 
Additional studies have been conducted to better define the key residues involved in 
antagonist binding. It has been suggested, with the use of docking techniques, that the 
binding site of an antagonist is larger than the one for an agonist, as typically 
antagonists are larger the agonists  (Xhaard et al. 2005).  Antagonist binding showed 
important hydrophobic interactions with TM6 and TM7 (F6.44, W6.48, F6.51, F6.52, 
and F6.53) (Gentili et al. 2004). Additionally, xl2.49 and xl2.51 (as well as 5.43) were 
found to be important in yohimbine binding (Laurila et al. 2007). 
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3. Aims of the Study 
The main goal of this study is to identify novel modulators acting on ABCC2 
transporters and α2-adrenoceptors subtypes and to understand their mode of action. 
With this purpose screening approaches and chemoinformatic analysis were used to 
identify novel modulators. In-depth experimental studies were performed to understand 
the interactions between ligands and proteins and their mode of action. 
 Find novel compounds for ABCC2 and the α2-adrenoceptors subtypes 
using screening approaches 
 Acquire insights into the binding profile, “instant SARs” and identify new 
modulators of ABCC2.  Publication II and Unpublished results 
 Identify α2-and α2B-adrenoceptors selective compounds. Publication IV 
 Perform chemoinformatics analyses of screening data on ABCC2 and the 
α2-adrenoceptors subtypes 
 Analyze, map the biological activities and represent the compound property 
space (similarity clustering). Publication II and Publication IV 
 Extract molecular descriptors important for discriminating ABCC2 inhibitors 
from inactive molecules. Publication II 
 Conduct an in-depth study of the mode of action of the compounds 
interacting with ABCC2 and the α2-adrenoceptors subtypes 
 Identify the specific effects of compounds on different ABCC2-mediated 
probe transport. Publication I and Publication II 
 Explain the 10- to 100- fold differences in binding differences among the α2A, 
α2B- and α2C- adrenoceptor subtypes. Publication III 
 Understand the relationships between compound structures and their 
biological activity using homology modelling 
 Identify the molecular interactions between α2-adrenoceptors and a set of 
antagonists. Publication III 
 Glean further insights into the interaction between ABCC2 and inhibitors. 
Unpublished results 
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4. Materials and methods  
In this section, a short summary of the materials and methods used is presented. The 
specific and detailed descriptions of the methods are found in the original Publications 
I-IV.  
4.1. Materials 
 Chemical compounds  
A small set of commercially available compounds were tested in Publication I and 
Publication III. In Publication I, eight compounds were selected from literature as 
known ABCC2 modulators, and used for the probe comparison in the vesicular 
transport assay (described below). In Publication III, nine known antagonists, selected 
as known α2-adrenoceptors antagonist, have been evaluated for α2-adrenoceptors 
chimera subtype binding affinity.  
In Publication II and Publication IV, a screening-type approach was used to identify 
active molecules. In Publication II, 432 compounds were tested with a vesicular 
transport assay. These compounds were of built using combinatorial and heterocyclic 
chemistry obtained through the collaboration of Professor Peter Wipf from the 
University of Pittsburgh, Center for Chemical Methodologies and Library 
Development. 
In Publication IV, 17,798 compounds were screened, 2112 of these molecules could be 
classified as FDA approved drugs, and the rest were defined as general compounds 
derived from the ChemDiv (San Diego, CA, USA), ChemBridge (San Diego, CA, 
USA), Tripos Discovery Research (now Exelgen Dis- covery, Bude, UK) and the 
MicroSource Spectrum collection (MicroSource Discovery Systems, Inc., 
Gaylordsville, CT, USA). 
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4.2. Methods 
4.2.1. Experimental methods 
 Protein expression and membrane preparation 
ABCC2 was expressed in a suspension of Spodoptera frugiperda insect ovarian cells 
(Sf9), while the α2-adrenoceptors subtypes were expressed in adherent Chinese hamster 
ovary cells (CHO) by the collaborators. Membrane preparation was quite similar for 
both proteins. The collected cell pellet was suspended in a hypotonic lysing buffer and 
homogenized, and subsequently centrifuged to remove nuclei and aggregates. 
Additional steps of centrifugation and re-suspension were needed to isolate the 
membrane fraction of the insect cells. Vesicles used in Publication I and Publication II 
were then prepared from a membrane suspension by passing through a 27-gauge 
needle. 
 Vesicular transport assay  
Vesicular transport assay (VT-assay) is the simplest method that can be used to predict 
interactions of compounds with transporters, as ABCC2, and thus to assess the liability 
of compounds for potential transporter-mediated DDIs. When combined with a 
detection technique, such as mass spectroscopy or when using labelled substrates, the 
VT-assay can also be used to give further insights into the actual transport. Inverted 
vesicles create a direct access point for the substrate to the transporter binding site 
(Brouwer et al. 2013) 
The VT-assay functions by measuring the ATP-dependent uptake of substrates into the 
vesicles. Uptake is detected by fluorometry, radioactivity, or mass spectroscopy 
(Figure 12, left side). The assay usually is used to indirectly measure the modulatory 
effect of the tested compounds on the transport of the detectable substrate probe 
(Figure 12, right side).  
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Figure 12 Vesicular transport assay. The ATP dependent uptake of the probe (orange) in the vesicle is 
measured. A modulator (blue) alters is added and the ATP depended transport of the probe(right side).  
After the test compound is added, the change of active transport of the probe is 
measured. Inhibitors decrease the transport of the probe, while stimulators will increase 
it. Compounds inhibiting/stimulating the ABCC2 transport may or may not be 
substrates, as they are not necessarily transported by the protein. It has been proposed 
that ABCC2 can co-transport compounds with glutathione; therefore, it was added to 
the assay (Rappa et al. 1997).  
Several commercial assays, optimized for vesicular transport with different ABC 
transporters are available. For the ABCC2 VT-assay, three substrate probes have 
optimized  these are : leukotriene C4 (LTC4), β-estradiol 17-(β-D-glucuronide (EG), 
and 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDCF) (Figure 13) (Chen et al. 1999; 
Bodó et al. 2003; Heredi-Szabo et al. 2008). In Publication I, VT-assays with all three 
probes were used; while only EG and CDCF assays were used in Publication II. 
EG  CDCF  LTC4 
 
 
 
Figure 13 ABCC2 VT-assay probes. EG, β-estradiol 17-(β-D-glucuronide; CDCF 5 (and 6)-carboxy-
2',7'-dichlorofluorescein; LTC4, leukotriene C4. 
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 Competition binding assay 
The competition binding assay was performed on α2-adrenoceptors subtypes by the 
collaborators using two antagonist radioligands, RX821002 (in Publication III) and 
RS79948-197 (in Publication IV). Briefly, before performing the assay, the equilibrium 
dissociation constant (Kd) and receptor binding site density (Bmax) were calculated to 
define the affinity of the radioligand and specific binding. In Publication III, the 
affinity of the radioligand was first determined for each of the mutated receptor with a 
saturation assay. 
In a competition binding assay, the displacement of the labelled ligand from the 
orthosteric site is detected. Ligands that bind to the orthosteric site will compete with 
the radioligand for the site. With this experiment, it is not possible to define the 
functional effect (agonist or antagonist) of the competing ligand. If the function effect 
is needed a functional assay has to be performed. In Publication IV, in addition to the 
competition binding assay, a functional [35S] GTPγS assay was performed. Such assay 
identifies the activation of the G-protein signalling pathway, specifically, it detects the 
guanidine nucleotide exchange (GDP > GTP) in the G-protein in the agonist activation  
(Peltonen et al. 1998).  
 Screening 
Screening, of a small/medium sized library was performed with either the VT-assay or 
with a competition binding assay. Generally, screening is often an automated 
biochemical assay set up that is used to assess the activity of a set of compounds. In a 
screening approach, a large set of compounds are tested initially, but usually only a set 
of active compounds called “hits” are selected for further analysis. With this approach, 
it is possible to maximise the number of tested compounds and minimize the costs. 
Screening performance can be evaluated statistically. The most common parameters 
that are calculated include the Z’, which is a parameter that defines if the assay 
response is large and clear enough to be seen in the assay setup; signal to background 
(S/B ratio), and  signal to noise (S/N ratio) (Eq. 12, Eq. 13, Eq. 14) (Zhang et al. 1999). 
The parameters are calculated as following, considering X as the mean of the 
calculated values, SD the standard deviation, B for minimum, and S for maximum 
accordingly. 
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Z’     𝑍′ = 1
3𝑆𝐷𝑠+3𝑆𝐷𝐵
|𝑋𝑆−𝑋𝐵|
             Eq. 12 
Signal to background ratio  𝑆/𝐵 =
𝑋𝑠
𝑋𝐵
              Eq. 13 
Signal to noise ratio   𝑆/𝑁 =
𝑋𝑠−𝑋𝐵
√𝑆𝐷𝑆
2−𝑆𝐷𝐵
2
             Eq. 14 
Screening approaches have been used with the aim of characterising ABCC2 
modulators in Publication II and identifying selective α2-adrenoceptors ligands in 
Publication IV. 
Additionally, in Publication IV, a miniaturization binding assay was used. 
Miniaturization reduces the amount of biological and chemical reagents used per assay, 
thus reducing costs. However, it may result in the loss of hit compounds due to low 
signal-to-noise ratios. 
 IC50 calculation and curve fitting 
IC50 is the molar concentration of an unlabeled agonist or antagonist that inhibits the 
binding of the radioligand by 50%; or in the case of transporters: the molar 
concentration that inhibits the probe transport by 50%. It is normally calculated from 
concentration-response curves (Figure 15) of inhibitors (Eq. 15). 
 
Figure 14 IC50 concentration-response curve 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑚𝑖𝑛 +
𝑚𝑎𝑥−𝑚𝑖𝑛
1+[(
[𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟] 
𝐼𝐶50
)]
−𝛽      Eq. 15 
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The Hill coefficient or β factor can be used to “better fit” the data to the Michaelis-
Menten equation where V0 is the transport rate at a specific moment; Vmax is the 
maximum transport rate; S is the substrate concentration; Km is the substrate 
concentration at half of Vmax. as following (Eq. 16) 
𝑉0 =
𝑉𝑚𝑎𝑥∗𝑆
𝛽
𝐾𝑚
𝛽+𝑆𝛽
              Eq 16 
In enzyme kinetics the Hill coefficient is correlated with cooperativity in binding that 
can be positive (>1) or negative (<1). This coefficient can define the number of 
cooperative binding sites but cannot indicate the number of functionally important 
binding sites. For competitive inhibitors the Hill coefficient should be 1 (Weiss 1997). 
In the case of transporters it has been suggested that these values are useful for fitting 
the experimental data but do not represent physical parameters (Bentz et al. 2005). 
For competitive inhibitors, additionally, it is possible to convert the IC50 to Ki utilizing 
the Cheng-Prusoff equation (Eq. 17). The equation can be used only in the case of 
competitive inhibitors and when the concentration of substrate is much higher than the 
IC50.  
𝐾𝑖 =
𝐼𝐶50
1+
𝑆
𝐾𝑚
     Eq. 17  
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4.2.2. Computational methods 
 Sequence alignment and homology modelling 
Computational methods have been developed to estimate the 3D structure of proteins 
when no crystal structure is available. These methods are divided in two major classes: 
template based (homology) modelling and de novo modelling. Of these methods 
homology modelling (or comparative modelling) is considered to be the more accurate 
and more commonly method used in drug discovery. The basic hypothesis that drives 
this method is the observation that proteins sharing a common ancestor (i.e. 
homologous proteins) exhibit the similar structure or fold (Chothial & Lesk 1986).  
This method depends on the use of the 3D coordinates of a homologous protein 
template structure and the sequence of the target protein. Different methods have been 
developed to build homology models and all share similar steps: 1. Identify known 
structures and align them to the target protein; 2. Define suitable template structure 
based on the alignment and the quality of the structure; 3. Build a model by replacing 
the atomic positions of the template with the amino acids present in the alignment; and  
4. Refine the model (Schmidt et al. 2014). 
There are several approaches used to align the target sequence to the template 
structure. Sequences can be aligned either pairwise, when the alignment is done with 
only the target and the protein, or with multiple alignments, where many homologous 
protein sequences are used. A structural alignment can be done for two or more 3D 
structures of proteins with a similar fold to identify stretches of amino acids that 
correspond to the structurally conserved parts of the protein. Generally, structural 
alignments are preferred as the structures reveal the real correspondence for the amino 
acids in the compared structures.  
In Publication III and Publication IV, the homology models for the α2-adrenoceptor 
subtype were built based on β2-adrenoceptor template structures. The target sequence 
was aligned to the structural alignment of more crystallized GPCRs.  
The homology model of human ABCC2 was built using mouse mdr1 as the template 
presented in the Unpublished results. The alignment was derived from a multiple 
alignment of the NBDs and TMDs of all 48 human ABC proteins (sequences retrieved 
from the Uniprot KB data base, The UniProt Consortium) 
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 Molecular docking 
Molecular recognition is a key feature in many biological processes and molecular 
docking aims to predict these interactions. Molecular docking is normally composed of 
two parts, the estimations of favourable low-energy binding poses and the 
ranking/scoring of these poses. Generally, many binding poses are obtained for one 
ligand, and thus, the poses have to be evaluated. The scoring of binding poses involve 
four general categories (Liu & Wang 2015): physics-based methods, empirical scoring 
functions, knowledge-based potentials, and descriptor-based scoring functions. Many 
scoring functions do not optimally define structural water molecules and the enthalpy 
contributions of the interaction are overlooked (Sousa et al. 2013).  
Docking programs are considered to perform relatively well in predicting ligand poses 
in comparison to their scoring and ranking function. Docking with GOLD™ (Jones et 
al. 1997) was used to dock antagonists in Publication III, and 2,2,-bisepigallocatechin 
digallete, in Publication IV. In both docking simulations, the aspartic acid D3.32 was 
used to define the central point of the binding cavity. At the time of the work, flexible 
protein docking was not available. To overcome the lack of this technology, many 
different homology models of the protein were built mimicking the flexibility of the 
side chains.  
ShaEP has been used for the ranking and selecting of the best docking pose of α2-
adrenoceptor antagonist in Publication III. ShaEP is a software that overlays molecules 
based on their shape and electrostatic potential (Vainio et al. 2009). All docked poses 
presented in Publication III, were ranked based on the comparison of crystalized 
ligand, carazolol, bound to β2-adrenoceptor.  
 Chemical scaffolds 
A chemical scaffold is the common core structure, or substructure, which characterizes 
a group of molecules (Schuffenhauer et al. 2007). Traditionally, molecules sharing the 
same scaffold are presumed to have the same synthetic pathway, e.g. combinatorial 
chemistry libraries. Scaffolds are generally a defined ring-system that keeps the 
substituents in their position (Ertl et al. 2006). 
The Markush structures were first used in a patent clam in 1924 and are now the most 
common way to represent molecules that share the same scaffold. In such 
representation the common core of the molecules is defined and the substitute 
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variations, the individual functional groups of each molecule, are given separately as 
R-groups (Figure 15). 
 
Figure 15 Markush structure. The first Markush structure published in the patent clam in 1924. 
A variant of the Schuffenhauer rules was used to divide the combinatorial library used 
in Publication II. Additionally, all the molecules have been described as Markush 
structures. Hierarchical clustering using maximal common substructure was used to 
classify hit compounds selected in Publication IV. 
 Structure- activity relationships 
The analysis of structure-activity relationships (SAR) is the central core of medicinal 
chemistry. The association between the biological activity of molecules and the 
chemical properties is fundamental to identify, optimize, and evaluate new potential 
drug targets. The assumption of any SAR method is that similar molecules have similar 
activity, and that it is possible to identify the crucial determinants correlating with the 
biological activity. Many methods have been developed, focusing on different 
chemical descriptors of the molecule or on different algorithms to correlate the 
descriptors to the activity.  
Supported vector machine (SVM) (Cortes & Vapnik 1995) and XY-fused Kohonen 
Networks neuronal network (Kohonen 1982) model were built to classify molecules 
into inhibitors and inactive molecules in Publication II. Both machine learning methods 
use an algorithm that recursively learns from the data identifying patterns for the 
classification. The SVM classification separates the data in two or more classes while 
the XY-fused Kohonen Networks defines the two classes based on self-organizing 
maps. 
Binary classification test was performed to validate the models. Initially, the number of 
true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN) 
are defined; consequently the accuracy, sensitivity, and specificity are calculated (Eq. 
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18, Eq. 19, Eq. 20). In addition to these parameters the Matthews correlation 
coefficient (MCC) was calculated (Eq. 21).  
Accuracy (%)   ACC (%) = 
𝑇𝑃+𝑇𝑁
𝑇𝑃+𝐹𝑃+𝑇𝑁+𝐹𝑁
                  Eq. 18 
Sensitivity (%)     SE (%) = 
𝑇𝑃
𝑇𝑃+𝐹𝑁
                  Eq. 19  
Specificity (%)     SP = 
𝑇𝑁
𝑇𝑁+𝐹𝑃
               Eq. 20 
MCC = 
𝑇𝑃×𝑇𝑁−𝐹𝑃×𝐹𝑁
√((𝑇𝑃+𝐹𝑃)× (𝑇𝑃+𝐹𝑁)(𝑇𝑁+𝐹𝑃)× (𝑇𝑁+𝐹𝑁))
            Eq. 21 
 Pharmacophore 
The term pharmacophore was first defined by Ehrlich in 1909 as the molecular 
fragment that carries the essential features for a drug’s biological activity. A 
pharmacophore can be created in a ligand-based manner, where a set of active 
molecules are superimposed and the common chemical features for activity are 
extracted, or in a structure-based manner by proposing possible interaction points 
between ligand and target (Yang 2010). Generation of ligand-based pharmacophores 
starts with the identification of all possible conformations of the active molecules, 
which are then aligned. The alignment can either: 
1. be point-based using least-square fitting of atoms, fragments, or chemical 
features 
2. properties-based, using molecular field descriptors and aligning them using 
Gaussian functions.  
Pharmacophores of ABCC2 inhibitors were built in a ligand-based manner using 
Discovery Studio (Accelrys Software Inc., Discovery Studio Modeling Environment, 
Release 4.0, San Diego: Accelrys Software Inc., 2013.). The automatically generated 
conformations of the ligands were aligned using a scaffold superimposition.  
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5. Summary of main results  
Results are presented according to the aims as in Section 3; unpublished results will be 
presented in the following Section (6). 
 Find novel compounds interacting with ABCC2 and the α2-adrenoceptors 
subtypes using screening approaches 
In Publication II, a small-size library of 432 compounds was used to acquire insights 
into the activity profiles of ABCC2 modulators. The library was initially tested at one 
data point at 80µM with two probes CDCF and EG (primary screening). From the 
primary data, we analysed the modulatory effect calculated as % inhibition of probe 
transport (%I) and grouped the results into five different classes (inhibitors, borderline 
inhibitors, inactive, borderline stimulators, and stimulators). Considering only 
inhibitors (I% < 50) and stimulators (%I > 150), 22% of the 432 tested compounds 
showed a modulatory effect. 
After the initial screening 86 compounds were selected for further analysis; initially 
three concentration points were calculated and from these 50 were selected for IC50 
calculations. In total, 25 EG and 38 CDCF inhibitors were identified, of these 23 
inhibited both probes. Additionally, of these 23 shared inhibitors, 16 had an IC50 lower 
than 30µM for at least one probe, four molecules are presented in Table 3.  
Only few probe selective modulators have been identified. One clear probe selective 
inhibitor 3j (50-fold difference between CDCF and EG inhibition) and another four 
(4d, 4f, 17 and 21) with potentially different type of modulation (with some 
uncertainties due to the only partial concentration-response curve) are presented in 
Table 4. 
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Table 3 A selections of four ABCC2 inhibitors. 1l, 2u, 6 and 29 with their relative calculated IC50, 
numbered as in Publication II. 
ABCC2 inhibitors 
 CDCF EG 
# Structure 
IC50, µM 
* 
(95% CI)  
Hill slope 
(95% CI) 
IC50, µM 
* 
(95% CI) 
Hill slope  
(95% CI) 
1l 
 
12 
(10 - 15) 
-1.4 
(-1.8, -1.0) 
9 
(4 - 22) 
-0.9 
(-1.5, -0.3) 
2u 
 
57 
(37 - 87) 
-1.4 
(-2.2, -0.7) 
15 
(4 - 57) 
-1.3 
(-3.3, -0.7) 
6 
 
23 
(14 - 38) 
-1.5 
(-2.4, -0.5) 
weak 
inhibitor 
a
 
 
29 
 
7 
(5 - 11) 
-1.1 
(-1.4, -0.7) 
inhibitor 
b
  
amodulatory effect estimated from three concentrations only (400µM,80µM,16µM); b4-parameter logistic model curve 
could not be fitted. * calculated at 400µM, 80µM,16µM,3.2µM, 0.64µM and 0.128µM. 
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Table 4 The five probe selective molecules. Molecules are numbered as in Publication II. 
Probe selective molecules 
  CDCF EG 
# Structure 
IC50
*, µM 
(95% CI)  
Hill slope 
(95% CI) 
IC50
*, µM 
(95% CI) 
Hill slope 
(95% CI) 
3j 
 
6 
(2 - 23) 
-0.9 
(-1.5, -0.2) 
305 
(220 - 423) 
-1.1 
(-1.7, -0.4) 
4d 
 
37 
(14- 97) 
-0.6 
(-0.9, -0.3) 
weak 
inhibitor a 
 
4f 
 
inactive a  
70 
(18 - 283) 
-1.0 
(-2.1, 0.1) 
17 
 
stimulator  inactive a  
21 
 
220 
(173 - 279) 
-1.6 
(-2.1, -1.1) 
stimulator a  
amodulatory effect estimated from three concentrations only (400µM,80µM,16µM ); b4-parameter logistic model curve 
could not be fitted. * calculated at 400µM, 80µM,16µM,3.2µM, 0.64µM and 0.128µM. 
Summary of main results 
 
 
48 
 
In Publication IV, a mid-sized library (of 17952 molecules) was screened with a 
miniaturized competition binding assay to identify α2B– adrenoceptors selective 
compounds. The library could be divided in two subset, approved drugs, and general 
compounds (defined as in section 4.1). From the initial screen, tested with a single 
concentration of 10µM concentration against the human α2B-adrenoceptor, 176 
preliminary hits were selected. These preliminary hits were then retested at 1µM 
concentration so only high affinity molecules could be identified. After this second 
selection, 93 molecules were selected to be further characterized. The 93 molecules 
showed to have an affinity in the low µM- nM range towards the α2B-adrenoceptor 
(defined as Ki values). Of these molecules, twelve molecules were approved drugs one 
of the three were of the general subset. Of the twelve molecules selected from the 
approved drugs subset four were α2B-adrenoceptor selective, six favoured α2A-
adrenoceptor, while two were selective for α2C-adrenoceptor (Table 5). Interestingly, 
promethazine was not known previously to be active towards α2-adrenoceptors and 
showed to be α2B-adrenoceptor selective (Table 5). In addition to the selective 
approved drug molecules two new α2-adrenoceptors selective compounds were 
identified from the general subset (Table 5). 
Table 5 Subtype specific molecules (continues on the following pages 49-50). 
Subtype selective molecules 
 α2B α2A α2C 
Name Structure 
Ki, nM 
(95% CI)  
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
Promethazine 
 
160 
(87-286) 
n.d# n.d# 
Periciazine 
 
5.2 
(1.5-23) 
307 
(111-715) 
121 
(49-287) 
2-Methoxyidazoxan 
 
16 
(6-35) 
0.67 
(0.28-1.4) 
5.1 
(2.6-8.5) 
Clozapine 
 
31 
(13-68) 
132 
(40-308) 
20 
(4-26) 
#IC50 was not calculated as the percentage inhibition at 1µM higher than 50%. 
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Continuation of Table 5. 
  α2B α2A α2C 
Name Structure 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
Propiomazine 
 
74 
(42-133) 
747 
(423-1318) 
813 
(89-633) 
Perphenazine 
 
95 
(23-252) 
917 
(294-3468) 
285 
(89-633) 
Chlorpromazine 
 
151 
(82-307) 
1762 
(953-3259) 
442 
(248-819) 
Guanabenz 
 
349 
(94-1013) 
21 
(11-36) 
236 
(123-688) 
Naphazoline 
 
476 
(109-1613) 
10 
(4-25) 
410 
(237-708) 
Tetrahydrozoline 
 
1034 
(584-1830) 
44 
(19-86) 
n.d 
Bromocriptine 
 
1260 
(321-6720) 
98 
(35-227) 
1770 
(388-5866) 
Nicergoline 
 
2699 
(1425-5608) 
185 
(49-424) 
362 
(185-722) 
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Continuation of Table 5. 
 α2B α2A α2C 
Name Structure 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
ChemDiv 
C712-1339 
 
845 
(367-2027) 
75 
(22-220) 
124 
(44-287) 
ChemDiv 
1724-0247 
 
923 
(458-2081) 
34 
(18-62) 
142 
(86-250) 
 Perform chemoinformatics analyses of collected screening data on ABCC2 
and the α2-adrenoceptors subtypes 
In Publication II, SOM maps are used to map the activities of the modulators on the 
chemical space. Such maps provide a simple way to visualise the activity data. From 
the maps it was observed that modulators and inactive molecules cluster in different 
chemical spaces. Additionally, the data obtained from the primary screen was used to 
build a supported vector machine (SVM) predictive model. The tested SVM model was 
able to discriminate between inactive compounds and inhibitors and predict the correct 
class with an accuracy of 66% (calculated with an external dataset). As a result 
important discriminative features between inhibitors and inactive molecules have been 
identified, being the number of rings, the solubility, and the hydrophobicity. 
In Publication IV, a hierarchical classification tree of active compounds was 
constructed identifying 28 distinct scaffold/groups; of these ten were new scaffolds 
active on α2-adrenoceptors. Of these ten scaffolds, two were identified as interesting 
scaffolds to further develop for subtype selective molecules, thienochromenes (as in 
ChemDiv C712-1339) and pyridopymidines (as in ChemDiv 1724-0247) presented in 
Table 5. This scaffold tree was provided as a tool to facilitate the visualisation and the 
analysis of the screening results.  
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 Conduct an in-depth study of the specific mode of action of the compounds 
interacting with ABCC2 and the α2-adrenoceptors subtypes 
In Publication I, the VT assay (using either CDCF, LTC4, or EG as substrate probe) 
was utilised to decipher and characterise the specific effects of compounds on the 
ABCC2-mediated probe transport. Eight reference compounds selected as known 
ABCC2 modulators from literature were tested in the assay with the different probes. 
Three compounds had probe-independent effect; quercetin inhibited the transport of all 
three probes, while disopyramide and paracetamol did not effect at all the probe 
transport. Of the probe dependent modulators indometacin, diclofenac, and estrone-3-
sulphate showed inhibition of CDCF and LTC4, while they stimulated EG transport.  
Budesonide and thioridazine inhibited EG transport, while they stimulated CDCF 
transport and did not affect LTC4 transport. In addition, the IC50 for inhibitors were 
calculated showing additional probe selectivity based on a different degree of 
inhibition of the probes (for example indomethacine inhibits both LTC4 and CDCF 
with IC50 of 246 and 75 respectively). The probe selective molecules are presented in 
Table 6. 
Table 6 Probe selective compounds selected from Publication I. (continues on the following page). 
Probe selective molecules 
  LTC4 CDCF EG 
Name Structure IC50, µM IC50, µM IC50, µM 
Indomethacin 
 
246.6 ± 23.8 75.7 ± 12.9 Stimulates 
Diclofenac 
 
233.6 ± 47.5 177.3 ± 15.0 Stimulates 
Estrone-3-sulfate 
 
97.9 ± 19.4 122.2 ± 1.4 Stimulates 
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Continuation of Table 6. 
  LTC4 CDCF EG 
Name Structure IC50, µM IC50, µM IC50, µM 
Budesonide 
 
Indifferent Stimulates 60.3 ± 6.1 
Thioridazine 
 
Indifferent Stimulates 40.9 ± 7.2 
In Publication II, five possible probe selective molecules are presented in Table 4. 
Additionally, to further analyse the probe effect, primary screening results were 
compared between CDCF and EG modulation. The modulatory effect of the two assays 
showed an agreement of 91%, when considering the classification as inhibitors, 
inactive compounds, and stimulators. When the correlation was calculated between the 
percent inhibition of CDCF and EG, the correlation decreased to a 0.36. The probe 
effect here identified is not as common as it might be inferred from Publication I. 
 In addition, the robustness presented in supplementary material in Publication II 
shows that the standard deviation of the individual points calculated at the different 
concentrations was lower for the CDCF assay than for the EG assay. The average of 
the standard deviation ranged between 5-11% for the CDCF assay and 10-20% for the 
EG assay.  
In Publication III, eight chimeric α2-adrenoceptors were constructed with either N-
terminus-TM1 swapped between the three subtypes or only the TM1 (maintaining the 
wild type N-terminus) with the aim of identifying subtype selective features. Nine 
known α2-aderenoceptors antagonists have been used, and the affinities of these 
molecules to wild type receptors and chimeras have been defined with a competition 
binding assay. For three bulky antagonists (spiperone, spiroxatrine, and clorpormazine) 
the competition binding assay found a lower affinity, for α2A-adrenoceptor when 
compared to the binding affinities to α2B- and α2C-adrenoceptor wild type. Chimeras 
with N-terminus-TM1 swapped between α2A- and α2B-adrenoceptors showed a 
significant increase of affinity for spiroxatrine and clorpormazine. Similarly, chimeras 
with N-terminus-TM1 swapped between α2A- and α2C-adrenoceptors showed the 
increase of affinity for all of the three antagonists. Additional experiments showed the 
involvement of the only TM1 in the ligand recognition, and not the N-terminus. As a 
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consequence of these experimental results it was shown the involvement of TM1 in 
bulky antagonist binding. These experimental results combined with the molecular 
modelling results suggested that TM1 does not directly affect the ligand bind, 
nevertheless influencing the binding indirectly.  
  Understand the relationships between compound structures and their 
biological activity using homology modelling 
In Publication III, homology modelling and docking simulation have been used to 
define the involvement of TM1 in the binding of three bulky antagonists. Homology 
models of the three subtypes were built using β2-adrenoceptor as the template. A 
comparison of these new β2-adrenoceptor based models were a compared with the 
rhodopsin based model previously published. The β2-adrenoceptor based models 
showed a: 1. Shorter and wider binding cavity; 2. Longer TM1-TM5 distance (by 3 Å); 
3. Presence of a α-helix extracellular loop position closer and deeper in the binding 
cavity; 4. The xl2.49 residue less exposed to the binding cavity; 5. The xl2.54 residue 
more exposed to the binding cavity. To better assess the interaction in the orthosteric 
site of the antagonist docking, simulations have been performed. After pose selection, 
using ShaEP, the docking poses showed interaction with both D3.32 and serine 
residues in TM5 but no direct interaction with TM1 (Figure 16A). Docked ligands 
were unable to interact with TM1 due to the longer distance between TM1 and TM5 
present in β2 adrenoceptor based models, and due to the occluded space by the residues 
of TM2 and TM7. 
 
Figure 16 Docking results on α2A-adrenoceptors. On the left figure Docked antagonist (green) do not 
interact directly with TM1 (in blue). In yellow carazolol, crystallized ligand in β2-adrenoceptor was used 
as reference to select docking poses. On the right figure The best ranked docking pose (in blue), 
interactions with S3.32, S5.43 and S5.46 are marked.  
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In Publication IV, a strong inhibitor, non-amine, non-protonable compound 2',2'-
bisepigallocatechin digallate was found, containging a catecholic group (also present in 
endogenous catecholamines) (Table 7). Non-charged ligands are unknown to date for 
α2-arenoceptors. Docking studies showed that 2',2'-bisepigallocatechin digallate could 
fit in the orthosteric site and interact with D3.32, S5.42 S5.43 and S5.46 thus, 
suggesting a direct interaction with the receptor binding site (Figure 16B).  
Table 7 Binding affinity of 2',2'-bisepigallocatechin digallate. 
Affinity for 2',2'-bisepigallocatechin digallate 
 α2B α2A α2C 
Structure 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
Ki, nM 
(95% CI) 
 
91 
(46-176) 
14 
(6-29) 
18 
(7-45) 
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6. Additional unpublished results 
A brief SAR analysis was included in Publication II, and the project was continued in 
order to gain additional insights of the SAR of ABCC2 modulators and to explore how 
the found inhibitors could interact with the binding cavity in ABCC2. Some of the 
unpublished results from these experiments follow.  
Additional concentration-response curves of 118 compounds were measured using the 
vesicular transport assay CDCF assay, as used in Publication I and Publication II 
(presented in section 4.2.1). The analysis was restricted to the CDCF assay based on 
the findings in Publication II, a good agreement between the results obtained from the 
EG and CDCF assay and constantly a more robust data producible with CDCF assay. 
These additional compounds were selected from the University of Pittsburgh, Center 
for Chemical Methodologies and Library, the same library used to select the 
compounds used in Publication II.  
In these unpublished results, my co-researchers and I identified 16 compounds from 
this test set with an IC50 lower than 30µM. More than half of the tested compounds (72 
of 118) belong to one of the four scaffolds presented in Publication II, while the 
remaining 46 compounds share a new benzenesulfonamide scaffold. Here, the 
preliminary SAR results for 4-phenyl-3,4-tetrahydropyrimindin-2-one analogues are 
presented in Table 8.  
Within this subscaffold (Figure 17), all molecules have butyric acid in position R1 and 
a methyl group in R4. The variation in the R2 and R3 groups are shown in Table 8, a 
total of 23 molecules of which three are inactive, seven are weak inhibitors, and 13 are 
inhibitors. 
 
Figure 17 The Markush representation of Scaffold 2. 
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Table 8 Structure activity relationships of scaffold 2B. Here are presented the variation of R2 and R3 
substituents. In bold font the compound code. In normal font IC50 (95% confidence interval). Inhibitor, 
weak inhibitor and inactive classes were assigned when IC50 was not possible to calculate. Assignment of 
classes was made on at least three concentration points, inhibitors have predicated IC50 lower than 100µM 
and weak inhibitor between 100 and 400µM.  
-R3 
-R2 
 
-CH2CH3 -CH2CBr3 -CH3 
4-Cl 
2r 
47 (31-72) 
  
2l 
inactive 
4-Br 
2ag 
51 (31-83) 
 
2at 
inhibitor 
 
4-NO2 
2ad 
weak inhibitor 
   
4-OCH3 
2t 
135 (66-278) 
   
3-OCH3 
2v 
97(72-132) 
   
2-Cl 
2s 
58 (43-79) 
   
3-NO2  
2aj 
inactive 
2ar 
25 (16-37) 
 
2-Cl; 3-Cl 
2au 
15 (13-17) 
   
2-Cl; 4-Cl 
2ah 
140 (86-227) 
   
-H 
 2ab 
inactive 
2i 
85 (63-114) 
2as 
31 (26-38) 
 
2-NO2; 4,3   
   
2u 
57 (37-87) 
4,3  
2ae 
79 (68-92) 
2j 
71 (47-107) 
  
2,3  
   
2k 
weak inhibitor 
2,3 ; 5,4  
 
2n 
31 (26-37) 
  
4,3  
2ac 
weak inhibitor 
   
4-  
   
2m 
weak inhibitor 
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Within this group of molecules, the strongest inhibitor showed an IC50 of 15M (2au). 
Some indications on position selectivity for the substitution is shown to preference the 
ortho-meta substitution compared to ortho-para one, as 2au has ten times higher 
affinity then 2ah. Halogen substitution as in 2ar and 2as lead to more active 
compounds compared to aliphatic hydrophobic substitutions. Additionally, the three 
molecules (2j, 2u and 2ae) with 1,3-oxolanein modification at R3 have an IC50 lower 
than 80µM, indicating that this substituent could be important for inhibitory activity. 
Additionally, a pharmacophore with shared features was built in order to illustrate the 
spatial arrangements of features. The identified pharmacophore for this scaffold 
showed two hydrophobic features and two hydrogen bond acceptor features shared 
between all active molecules (Figure 18). 
 
Figure 18 Pharmacophore of Scaffold 2B. Hydrophobic feature (blue), Hydrogen bond donor feature 
(green), compound 2au is represented as sticks.  
In order to suggest further molecular interactions at the binding site, the homology 
model of ABCC2 (Figure 19) was built. The mouse mdr1 was selected as the template 
for protein modelling (Li et al. 2014). The alignment (Figure 20) was obtained from a 
multiple alignment aligning in which both TMDs and NBDs were aligned 
independently. There are uncertainties in the alignment of several helices and, 
therefore, the model is useful only to get an impression of the possible charge and the 
size of the binding pocket. 
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Figure 19 Homology model of ABCC2, with identified the proposed binding site. TMD1 and NBD1 in 
blue (dark and light); TMD2 and NBD2 in green dark and light respectively. Box identifies the binding 
site, surface is coloured based on hydrogen bond donor (pink) and hydrogen bond acceptor (green) areas. 
The comparison of the pharmacophore model with the predicted binding cavity in the 
homology model of ABCC2 should be useful in suggesting the amino acid 
counterparts of interactions that could be later tested using site directed mutagenesis. 
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Figure 20 Sequence alignment of ABCC2 and mdr1a. The Predicted secondary structure of ABCC2 
based on the mouse mdr1 crystal structure (pdb code 4M2S).
  
60 
 
 
 
  
Discussion 
 
 
61 
 
7. Discussion  
 Identify novel compounds using screening approaches  
It is unavoidable that screening, and especially High Throughput Screening (HTS) 
programs, include false negatives and false positives among the real hits. False 
negatives normally occur if the assay is not sensitive enough. In addition, the 
compounds on the plate may have degraded. Poor solubility and resulting precipitation 
may decrease the actual tested concentration, leading to a decreased signal, or in some 
cases to false negatives. In a screening campaign, it is usually considered acceptable to 
“lose” some hits. On the other hand, when a screening approach is used to establish a 
chemical profile, then it is important that all data points are reliable. 
False positive hits are compounds that chemically react to the protein but do not have 
any biological activity. Hits can be validated, and false positive eliminated, using 
orthogonal assays. False positives may occur for several reasons; identifying a “false 
hit”, is described in Baell & Holloway 2010. Compounds can interfere as aggregates 
altering the assay itself or can absorb or can emit at the detected wavelengths altering 
the detection. Impurities deriving from the synthesis route, like metals that can react 
with an oxygen singlet or alter the redox cycle producing reactive oxygen species, can 
directly inhibit the protein activity. EDTA or other chelating agents can sequester 
important co-factors like metal ions, directly altering the proteins function. Other 
examples of compounds that could cause false positive hits are sticky compounds that 
bind non-specifically to the protein, or molecules that covalently bind to the protein 
altering the function without binding directly to the binding site (Baell & Holloway 
2010). 
Frequent hitters are compounds that recursively appear as hits in all types of assay, 
merely because they interfere with the assay itself. It has been strongly suggested to 
eliminate such compounds both from screening libraries and from any type of SAR 
analysis (Baell et al. 2013). To eliminate the frequent hitters, the Pan Assay 
Interference Compounds (PAINS) has been developed, filtering out the compounds 
with a substructure that has been found in frequent hitters (Baell & Holloway 2010). 
In Publication I, polyphenols compounds such as quercertin can precipitate in the assay 
conditions thus leading to false positive result (Pohjala & Tammela 2012). Quercertin 
was identified to be an inhibitor of all three probes, this suggests it to either be a real 
inhibitor or a false positive hit interfering with all three assays. 
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In Publication II, some inactive compounds were selected for retesting to limit the false 
negative hits. Several potential frequent hitters can be identified, for example scaffold 
1, the tetra-hydro-quinoline. According to the PAINS, tetrahydroquinoline scaffolds 
displays a 135% enrichment of hits per assay in bioassay databases, and this could 
interfere with the assay or the detection techniques. Such a scaffold could interfere 
photometrically with the CDCF assay due to intrinsic fluorescence or quenching 
effects thus altering assay detection/results. This can be taken into account determining 
the fluorescence, or quenching effect or using a non-fluorescent probe such as EG. In 
the specifics, scaffold 1 has showed highly consistent inhibition profiles between 
CDCF and, EG (a non fluorescent assay) confirming the activity of such scaffold.  
A typical HTS hit rate is between 0.5% and 5.0%, depending essentially on the 
druggability of the target protein and on the selected threshold to consider a compound 
to be active, which in turn depends on the target and on the aims of the project. Too 
high threshold will select too many molecules for further evaluation; too low threshold 
will limit the hits to a very small selection of highly active compounds. 
in Publication IV, the hit limit was set to 50% inhibition to select only strong binders at 
a tested concentration of 10M. The resulting hit rate was 0.98%, and the 176 
molecules identified as hits were then re-tested in a single-concentration assay (1µM). 
The aim of the project was to identify high affinity (low Ki) α2-aderenoceptor 
modulators and subtype selective molecules. Many active compounds already were 
known. 
Additionally, 2',2'-bisepigallocatechin digallate was identified as a new α2-
adrenoceptors inhibitor with nM affinities, this compound has been later mentioned to 
be highly promiscuous, possibly identifying it as a false positive hit. 
 Specific mode of action and relevance to the in-vitro methodologies 
Publication I and Publication II, VT-assays are based on active, ATP-dependent, probe 
transport. The active probe transport is measured by subtracting the uptake into the 
vesicle in the absence of ATP (mainly passive diffusion) from the active transport 
measured in the presence of ATP. Passive probe transport is detected either without 
ATP or by adding an non-hydrolysable ATP, such as AMP-PNP, which allows the 
interactions of the NBD but not the hydrolysis (Pratt et al. 2006). The comparison of 
both assay setup did not show significant difference (data not shown), thus in the 
assays used in Publication I and Publication II only an assay buffer was used as 
control.  
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Human ABCC2 transporters were overexpressed in Sf9 insect cells after a baculovirus 
transfection. Insect cells have been selected because of their high expression levels and 
low cost. Background activity, due to endogenous ATP transporters, can be detected 
and require control measurements. In Publication I, vesicles from β-galactosidase 
transfected cells were used as a control to validate the ABCC2-ATP dependent 
transport of the three probes.  
The use of stable cell lines (such as Sf9 insect cells) allows researchers to generate 
large batches that can be prepared and cryopreserved. Transporter activity is known to 
vary from batch-to-batch, thus the usage of larger batches can decrease the batch to 
batch variation. Additionally, an advantage of using the VT-assay in respect to cell 
based systems is the possibility to preload buffers and substrates, making it more high-
throughput then a cell based assay.  
Membranes obtained from Sf9 insect cells differ from mammalian cells, one major 
difference being the much lower concentration of cholesterol in insect cell membranes 
(Kodan et al. 2009; Marheineke et al. 1998). For some ABC transporters, e.g. 
cholesterol it is usually added in ABCG2 expressing Sf9 vesicles. (Pal et al. 2007). 
Similarly, ABCC2-transport could be affected by cholesterol. LTC4 mediated transport 
has respectively Km values that varies between 1µM (in MDCKII membrane) to 
0.690µM (Sf9 cells). Nevertheless, the effect of membrane cholesterol has not been 
clearly studied (Cui et al. 1999; Heredi-Szabo et al. 2008; Bakos et al. 2000). In 
addition, transporters expressed in Sf9 cells tend to be less glycosylated and this can 
alter the transport kinetics. However, this did not seem to effect ABCC2-mediated 
transport (Bakos E et al. 1996). 
Moreover, it is important to consider the effect of the co-substrates and co-factors, such 
as GSH or Mg
2+
, which can alter the kinetic parameters. The concentration of co-
substrates and co-factors can be a limitating factor for transport, for example Mg
2+
 is 
important for the ATPase activity. Some evidence suggests that glutathione is often 
added to the assay reaction since some molecules need it to be transported by ABCC2 
(Paulusma et al. 1999). This addition is still strongly debated (Borst et al. 2006). In 
Publication I and Publication II, glutathione was added; as it was not possible to rule 
out if for some of the tested molecules glutathione would be an important co-factor for 
modulation. 
For inhibition studies, like in Publication I and Publication II, the probe substrate was 
shown to have a central role in the evaluation of inhibitors. Optimal probe compounds 
should be characterized by active transport, low apparent permeability, and low 
nonspecific binding (to vesicles, filters, and assay plate). The three probes used in these 
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studies have been recommended as the preferred probes in ABCC2 VT-assays 
(Hillgren et al. 2013). 
Similar permeability restrictions apply even for modulators, as very lipophilic 
compounds, in addition to non-specific binding, can partition with the membrane, 
disrupting the structure and making them more permeable (leaky), thus altering the 
kinetic measurements. To limit the passive permeability, extensive membrane 
partitioning and unspecific binding to the membrane, it has been recommended to stop 
the reaction with ice-cold buffer and quickly filter the excess buffer away. 
 Probe-dependent transport in ABCC2-mediated transport 
In Publication I and Publication II, the reason behind the probe-dependent modulation 
is not known. One hypothesis is due to the different transport mechanisms of the two 
probe substrates (EG and CDCF). CDCF transport can be described by the classic 
Michaelis-Menten curve, identifying one single binding site.  EG transport instead 
displays a sigmoidal curve that indicates two possible co-operative binding sites 
(Zelcer et al. 2003; Bodó et al. 2003).  
 TM1 involvement in antagonist binding on α2A-adrenoceptors 
In Publication III, TM1 is the least conserved transmembrane helix of the seven helices 
in α2-adrenoceptors. It has previously been shown that other GPCRs involve TM1 in 
binding: for example in H1 receptors, the residues 1.35 and 1.39 and in rhodopsin the 
residues 1.49 and 1.50 interact the ligand (Strasser et al. 2008; Shi et al. 2001). In 
Publication III, it was shown that TM1 influences the binding affinities of three large 
antagonists. Molecular docking showed that these antagonists most likely cannot bind 
simultaneously in the orthosteric site and interact with TM1. Therefore, an indirect 
effect was proposed which could involve the receptor over all transmembrane packing 
and dynamic movement of the receptor.  
Additional caution should always be observed when analysing results obtained from 
chimera experiments. Mutated receptors are not biologically and physiologically 
relevant. Swaps in TM1 can affect the overall packing of the TM helix and the shape of 
the binding pocket, affecting the affinity of the ligand but without a direct contact. This 
study has been continued by creating half α2A-adrenoceptors and α2C-adrenoceptors 
chimeras showing that the half C-terminal domain of α2C-adrenoceptors is important 
for low receptor expression and drug selectivity, highlighting (extracellular loop2, 
intracellular loop 1 and C-terminal) as possible regions involved in selectivity (Jahnsen 
& Uhlén 2013). 
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 Homology models used to understand the ligand biological activity 
The usefulness of homology models depends on their quality. An important factor 
when evaluating homology models is the sequence identity between the target and the 
template and the correctness of the alignment.  
It has been estimated that if the sequence identity between the template and the target 
is higher than 50%, the calculated rmsd (from the experimental structure) is of about 
1Å; while for two sequences that have a sequence identity of 30–50%, the overall 
structural similarity is estimated to be approximately 80% with an rmsd of 2-3Å (with 
the majority of the errors in the loop prediction). When the sequence identity drops to 
20-30%, the structural similarity is predicted to be only 55%, which can decrease to 
20% with a lower sequence identity (Kryshtafovych et al. 2005). As a reminder, 
homology models are only models and cannot represent the reality better than the 
template itself (low resolution structure, low resolution model). In addition, models do 
not represent the full dynamic picture of the protein flexibility and the conformational 
changes that occur upon protein-ligand binding. Additional inaccuracies will occur due 
to the natural evolutionary divergence between the target and the template.   
Homology models have been built to better understand the structural determinants in 
the ligand binding of α2-adrenoceptors. Initially, models were based on 
bacteriorhodopsin and frog rhodopsin. Using these models, it was possible to identify 
only the general seven transmembrane helices and the general localisation of binding 
cavity residues (Mizobe et al. 1996; Salminen et al. 1999).  In 2000, when the bovine 
rhodopsin finally was crystalized with 2.8 Å resolution, it was possible to increase the 
resolution of the previous models (Rosenbaum et al. 2007). In the last 5-10 years, 28 
unique GPCR have been crystallized, but the α2-adrenoceptor is still lacking (Vroling 
2014). 
In Publication III and Publication IV, the homology model of α2-adrenoceptors 
subtypes is to be considered reliable and predictive. The models were built on the 
alignment with the β2-adrenoceptor where a higher level of sequence identity is present 
in the TM regions (the calculated sequence identity varies between helix between 37-
43%).This has been illustrated in the GPCR dock competitions (2008, 2010, 2013) that 
a sequence identity of 35-40% is the empirical cut-off for reliable homology models of 
GPCRs (Kufareva et al. 2014) . 
In the unpublished data, it was not possible to achieve a high sequence identity for 
ABCC2 – template (mdr1) alignment, since the overall sequence identity was 18% 
(with 30% in the NBD and only 10% TMD). The mouse mdr1 was selected as template 
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for the ABCC2 model, since it is one of the crystal structures with the highest sequence 
identity and due to the presence of a co-crystallized inhibitor cyclic-tris-(S) 
valineselenazole (QZ59-SSS). ABCB10 showed a bit higher sequence identity with 
ABCC2 (22% versus 18% with mdr1) but it has been crystallized in the closed 
conformation and does not have a co-crystallized ligand.  
Due to the low sequence identity between the target and the template, uncertainties are 
present in the predicted model. Therefore it is not possible to define the exact position 
of the amino acids in the model and, as a consequence, the interaction between ligands 
and transporter. Even if the predictive model presents some uncertainties, it can 
describe in a general (non-specific) way the characteristics of the ABCC2 binding 
cavity. Additional uncertainties are the model come from the TMD0 that is not present 
in the template but present in ABCC2 and, therefore, cannot be reliably modelled.  
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8. Conclusions and perspectives  
Many molecules are known to interact with the ABCC2 transporter, and some of them 
are transported. As a future prospective, it would be interesting to define which of 
these modulators are actually transported (the current VT-assay does not detect actual 
transport). In addition, it would be interesting to increase the number of concentration 
points in the determination of the IC50, to reduce the uncertainty in the results, and to 
lower the highest concentration point (400µM) reducing the risk of precipitation 
associated with poorly soluble compounds. Controls with mock cells could be added 
for each tested compound to take into account the possible transport/existence of insect 
ABC transporters.  
In Publication I and Publication II, probe-dependent modulation was studied showing 
that some modulators are probe-dependent. An hypothesis that can explain this probe-
dependence is the different transport mechanisms of the probes. Several studies have 
proposed that ABCC2 does not have one single well defined binding site, but possibly 
two sites that can cooperate in the transport of substrates. Probe selective modulators 
could be helpful in understanding the mechanism of transport of the probes and the 
reason behind such different modulatory effects. Another explanation that is not ruled 
out in the current settings is an artefact in measurements due to intrinsic fluorescence 
or on CDCF fluorescence quenching.  
In Publication II, as a results of the comparison the two assays, it was shown that 
CDCF assay is more robust then the EG assay. Identifying the CDCF assay is more 
attractive for future screening projects, thanks even to the lower cost of fluorescent 
assays (CDCF assay) respective of the radiolabeled ones (EG and LTC4 assay).  
There is a need for α2-adrenoceptors subtype specific molecules that can be used in the 
treatment of high blood pressure, in the alleviation of withdrawal syntomes by 
inhibiting the processing of sensory information, and as anaesthetic with a safer 
therapeutic profile compared to the drugs currently used that are non-selective. The 
known α2-adrenoceptors subtype-selective drugs have a Ki in the order of low nM. The 
compounds that have been identified with miniaturized HTS in Publication IV have 
shown to have similar Ki on the low nM range and, thus, are ideal hits for further drug 
discovery optimisation. 
Challenges in designing subtype specific molecules are expected due to high structural 
similarity of the subtypes. Subtype specificity is still hard to address, as receptors share 
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a very similar binding cavity, suggesting that ligands are accommodated similarity. 
TM1 was shown to be involved in subtype determination of three antagonists in 
Publication III. However, docking results showed that ligands which bind to TM3 and 
TM5 do not have direct contact with TM1.  
Since the 3D structure of α2-adrenoceptors is not available, molecular models have 
been used to define the binding site, nevertheless, having an intrinsic uncertainty. The 
α2-adrenoceptors binding site has been defined in Publication III based on the β2 
adrenoceptors. Recently crystallized dopamine D3 receptor would be an interesting 
template to base a new homology mode of α2-adrenoceptors, having higher sequence 
identity.  
An additional value of Publication II and IV is the collection of two screening studies 
on ABCC2 and α2-adrenoceptors subtypes, measured under the same conditions and 
laboratory and, therefore, considered a perfect data set for further computational 
analysis. In the specifics of Publication II, it is the first large screening campaign 
performed with two probes. The data could be further utilized to predict transporter-
drug interactions or to develop SAR model for ABCC2 inhibitors.  
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